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ABSTRACT 
Molecular mechanisms of necrotic cell death in ischemic renal injury 
Yuan Ying, M.D., Ph.D. 
University of Nebraska, 2016 
Supervisor: Babu J. Padanilam, Ph.D. 
Acute kidney injury is a common clinical syndrome particularly in hospitalized 
patients. Necrotic cell death, as one type of major cell death after ischemic reperfusion 
injury, is partially responsible for the rapid decline in GFR. p53 is a novel apoptosis and 
necrosis inducer and is found to be activated after ischemic renal injury. Although 
previous studies suggest that p53 could be an important mediator of kidney dysfunction, 
no studies have examined its role in necrotic cell death and the cross talk between p53 
and other necrotic cell inducers such as PARP-1 and CypD. Thus, in this study our first 
goal was to examine the effect of gene ablation of p53 specifically in the proximal 
tubules on ischemic renal injury. Our second goal was to examine the possible 
mechanism by which p53 may induce necrosis. Our third goal was to test if double 
knockout of PARP-1/CypD or PARP-1/p53 additively/synergistically protects kidney from 
ischemic injury. Our results suggest that knockout of p53 specifically in the proximal 
tubules protected the kidney form ischemic renal injury by reducing apoptotic/necrotic 
cell death, inflammation, and long term fibrosis. Further, we found that double knockout 
of PARP-1/CypD or PARP-1/p53 in the kidney had better protective effects than 
respective single knockout mice. In addition, kidneys from double knockout mice also 
have better histological findings and fewer necrotic tubules. Our data demonstrate that 
activation of p53 significantly increased PARP-1 expression, which could contribute to 
necrosis in tubular cells. Furthermore, activation of p53 significantly decreased the 
expression of SLC7A11, a Glu/Cys carrier in cell membrane that inhibits ferroptosis. This 
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result suggests that p53-mediated ferroptosis might further contribute to tubular cell 
death after injury. Together, our data suggest that p53 is an important necrotic cell death 
inducer in ischemic renal injury. p53 may induce necrosis via overexpression of PARP-1 
and Bax, and promote ferroptosis by reducing the expression of SLC7A11 to induce cell 
death after ischemic renal injury. Our findings may have clinical implications for the 
pathogenesis of acute kidney injury, possibly providing potential therapeutic targets for 
this devastating syndrome. 
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INTRODUCTION1 
 
Acute kidney injury 
Acute kidney injury (AKI) is a common clinical syndrome that carries a high mortality 
rate. It has been estimated that AKI accounts for about 2 million deaths annually 
worldwide. The incidence of AKI among patients admitted into intensive care units is 
considerably high and is frequently associated with high mortality rates (110, 141, 151). 
Recent studies suggest that patients who recover from AKI have increased risk of 
developing chronic kidney disease (CKD); CKD is also a risk factor of incident AKI (22, 
119, 163).  
Currently, there is no effective treatment for this syndrome. Many rational 
pharmacological interventions based on pathogenic factors that elicit endothelial and 
epithelial cell injury, vasoconstriction, vascular congestion, leukostasis and reactive 
oxygen species generation, have failed or were inconclusive, mainly due to lack of 
understanding of the pathophysiologic processes of AKI (16, 106). Identification of 
mechanisms involved in renal regeneration after AKI might provide new therapeutic 
targets to protect kidney function and prevent complications. 
Pathogenesis of AKI 
AKI is defined by a rapid decline in glomerular filtration rate (GFR) in hours or days. 
Decreased GFR will lead to the retention of metabolic wastes such as creatinine and 
blood urea nitrogen (BUN), and imbalance of electrolytes, fluid, and acid-base (106). AKI 
                                                          
1 Some of the materials presented in this chapter were previously published: 1. Yuan 
Ying, Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted 
deletion of p53 in the proximal tubule prevents ischemic renal injury (183). 2. Yuan Ying 
and Babu J. Padanilam, Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D 
-overlapping pathways of regulated necrosis? (184) 
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represents a group of pathophysiological processes with different severities that result in 
a decline in GFR. Renal hypo-perfusion, renal parenchymal injury or obstruction of 
urinary flow are common causes of AKI and represent prerenal, intrarenal, and postrenal 
AKI respectively (16).  
While prerenal AKI is considered to be a reversible process, intrarenal AKI or acute 
tubular necrosis (ATN) with the involvement of the renal parenchyma is usually an 
irreversible event even with sufficient perfusion. ATN represents a severe form of AKI 
with selected tubular damage. Although all segments of the nephron may be injured 
under a severe ischemic insult, the proximal tubules, particularly the S3 segment of the 
proximal tubule (PT) in the outer stripe of outer medulla, is the most commonly involved 
segment because of its limited glycolytic capacity, high energy requirement, and 
persistent near hypoxia in this area (162). S1 and S2 segments are more likely to be 
injured by nephrotoxins because of active endocytosis in these segments. Tubular 
damage not only increases tubular fluid back leak, but also activates tubuloglomerular 
feedback as more solute is delivered to the distal nephron. Necrotic tubules can interact 
with tubular proteins to form casts in the downstream segments and obstruct the 
nephrons to increase glomerular back pressure. All these factors inevitably lead to a 
reduced GFR (16, 17). 
Animal models of ischemic renal injury 
Ischemic renal injury, caused by compromised perfusion of renal tissues, is accepted 
as the leading cause of AKI. Ischemia-reperfusion injury (IRI) in the mouse is an easily 
employed experimental model for the investigation of the pathological mechanisms 
implicated in this syndrome. Extensive work has demonstrated the usefulness of this 
model for the study of histological, cellular, and molecular signals in ischemic renal injury, 
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and most of the findings can also be extended to other kidney injury disorders that result 
in AKI. 
The warm IRI model using bilateral renal pedicle clamping is a common experimental 
model used in mouse and rat animals. It is different from the cold ischemia reperfusion 
model that mimics kidney transplantation. An ischemic period of 30 minutes duration 
results in moderate injury with histological changes comparable to human ATN. This 
model has been widely used to improve our understanding of the pathogenesis of AKI 
(171).  
Histological changes after intrarenal AKI 
Necrotic proximal tubules in the outer stripe of outer medulla represent the most 
dramatic findings evident by light microscopy after 30 minutes IRI in the mouse. Loss of 
brush borders and cell detachment from the basal membrane in the proximal tubule are 
also common findings. Tubular casts can be observed in downstream segments, with 
tubular dilation in the upstream cortical segments, although the glomeruli usually remain 
intact, at least under microscope. Those histological changes are directly related to the 
pathogenesis of AKI. As mentioned above, epithelial cell damage in the proximal tubule 
increases tubular fluid back leak. More fluid and solute are delivered to the distal 
nephron because of the inability to absorb solute in the proximal tubule, which activates 
tubuloglomerular feedback and reduces glomerular perfusion pressure. Cast formation in 
the downstream segments obstructs the nephrons and further reduces GFR. To some 
extent, histological damage can predict the kidney function (17, 171).  
Endothelial dysfunction and hemodynamic changes after intrarenal AKI 
Hemodynamic dysfunction is a major player in the pathogenesis of AKI. In many 
cases of AKI, a reduced renal blood flow is not sufficient to explain all of the change in 
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GFR (16, 17). The reduction in blood flow to outer medulla is greater than the decline in 
total renal blood flow. The medulla is relatively hypoxic in normal conditions due to the 
countercurrent exchange of oxygen between vasa recta, which is further occluded after 
AKI because of vulnerable anatomy of the capillaries (14, 18). Injured endothelial cells 
have exaggerated responses to mediators like endothelin-1 and angiotensin II but less 
responses to acetylcholine than normal renal vessels (17, 30). These factors together 
explain why this area has persistent hypoxia even when blood perfusion has restored for 
up to 2 days. 
Inflammation after AKI 
Inflammation plays an important role in the pathogenesis of AKI. Endothelial cells 
contribute to leukocyte migration by increasing the expression of intercellular adhesion 
molecule-1 (ICAM-1) and other adhesive molecules, which increases the rolling of 
leucocytes on the endothelial surface. Loss of endothelial cell-cell contacts also 
increases vascular permeability and promotes leukocyte migration. Tubular cell death 
might increase the release of intracellular contents such as fragmented DNA and 
enzymes which recruit not only innate immune responses involving neutrophils, 
macrophages, and NK cells, but also adaptive components such as dendritic cells and T 
lymphocytes. Shortly after AKI, those cells begin to accumulate in the kidney and last 
over several days after initial injury in mouse model. Inflammation after AKI causes 
further damage to the tubular cell. Reducing the inflammatory reaction after AKI can 
modulate the degree of injury (16, 17).  
Tubular repair and fibrosis after intrinsic AKI  
Tubular regeneration after AKI helps the kidney to restore normal function. It is clear 
that most regenerated tubular cells are derived from intrarenal cells rather than 
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mesenchymal stem cells or bone marrow stem cells that mainly exert paracrine effects 
to facilitate repair (77, 78, 103). Recent studies using lineage tracing techniques showed 
that damaged tubules mainly regenerate from intrinsic differentiated tubular cells. 
Surviving proximal tubular cells transiently dedifferentiate and adopt high regenerative 
capacities to repair injured tubular segments; however, the regenerated tubular cells are 
incomplete and often differ from normal tubules (181). This explains the long term risk of 
fibrosis and chronic kidney disease. Epithelial-mesenchymal transition (EMT) contributes 
to fibrosis because cells arrested at G2/M phase of the cell cycle generate transforming 
growth factor beta 1 (TGF-β1) and connective tissue growth factor (CTGF). The number 
of tubular cells arrested at G2/M can predicts the risk of long term fibrosis (180). 
Major types of cell death 
As important biologic processes, apoptotic cell death and autophagy are not only 
essential in normal development and homeostasis but also important in the 
pathogenesis of certain diseases. Autophagy is the basic catabolic mechanism that 
involves elimination of unnecessary or dysfunctional cellular components to preserve 
cellular homeostasis under baseline conditions and in response to stress. Autophagy 
also contributes to regulated cell death during embryonic development in Drosophila 
melanogaster and in the death of cancer cells exposed to chemotherapeutic agents, 
hypoxia, or specific autophagy-inducing peptides (49, 51, 52, 144).   
Apoptosis is adenosine triphosphate (ATP)-dependent and is characterized by cell 
and organelle shrinkage, membrane blebbing, chromosome condensation, apoptotic 
body formation and phagocytosis. Apoptosis is generally not associated with 
inflammation and is considered as a less harmful type of cell death. The apoptotic mode 
of cell death has been comprehensively reviewed by several investigators (27, 98, 109, 
132).   
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The third mode of cell death, necrosis, is ATP-independent and has its unique 
morphological characteristics such as increased cell or organelle volume (oncosis), 
mitochondrial swelling, rupture of the plasma membrane (cellular leakage), and 
consequent inflammation. Tissue detection of necrosis is usually defined in a negative 
fashion by excluding other types of cell death, such as apoptosis and autophagic cell 
death. Although the semiquantification of tissue necrosis is possible and mainly based 
on histology, its gross quantification remains a challenge.  
Regulated necrotic cell death 
As an important biologic process, cell death is not only essential in normal 
development and homeostasis but also important in the pathogenesis of certain 
diseases. In contrast to apoptosis, in which executive canonical pathway has been 
investigated and revealed in details, necrotic cell death was considered as a “passive” or 
“accidental” cell death and its molecular regulation remained largely unknown until 
recently. During last few years, more and more evidence suggests that necrotic cell 
death can be “programmed” and/or “regulated”. Multiple underlining pathways have been 
defined, such as necroptosis, parthanatos, ferroptosis, oxytosis, etc. Although these 
processes are characterized by their unique aspects of cell death processes, they also 
share some common features. Better understanding these different types of cell death 
may help us to understand the pathogenesis of certain diseases, thus provide some 
therapeutic targets for those diseases (50, 85, 115, 159). 
Although necrosis is usually defined in a negative fashion, it has its unique 
morphological characteristics that are not seen in apoptosis (53, 85, 97, 159). Apoptosis 
is generally not associated with inflammation and it is considered as a less harmful type 
of cell death, while necrosis usually induces inflammation.  A definite identification of 
necrosis in vivo may require electron microscope detection (97).  
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Apoptosis is initiated after the release of cytochrome c (cyt c) from mitochondria 
through outer mitochondrial membrane (OMM), which is formed by polymerization of 
Bax/Bak. Their insertion into the mitochondrial outer membrane generates a pore, 
leading to the leak of cyt c from the intermembranous space. In the contrast, necrosis 
involves the opening of inner and outer membranes of mitochondria. With increased 
permeability of inner mitochondrial membrane (IMM), it will no longer be able to generate 
ATP because of the loss of inner membrane potential. Clearly understanding the 
components of these transition pores across mitochondrial membrane is an important 
step to comprehend the mechanism of necrosis (71, 85, 115, 169). 
As mentioned above, the pathophysiologic abnormalities of IRI are characterized by 
changes in renal hemodynamics, tubular injury and inflammation. IRI leads to many 
secondary effects on the renal parenchyma including dysfunction of cellular energy 
metabolism, production of reactive oxygen species (ROS) and DNA damage, which 
leads to activation of the nuclear repair enzyme poly(ADP-ribose) polymerase-1 (PARP-
1) and the transcription factor p53. Activation of these molecules can induce necrotic 
and apoptotic tubular cell death, initiated by the opening of the mitochondrial 
permeability transition pore (MPTP), and outer mitochondrial membrane permeability, 
respectively (115, 116). Necrotic cell death in the proximal tubule after persistent 
ischemia translates a transient kidney dysfunction into irreversible kidney damage. Thus, 
focusing on the mechanism by which epithelial cells execute necrosis has the promising 
potentials to identify new therapeutic targets.   
MPTP-mediated necrotic cell death  
 Although necrotic cell death has generally been considered as passive, blocking the 
functions of several molecules, including cyclophilin D (CypD), PARP-1 and receptor-
interacting serine/threonine-protein kinase 1 (RIP1) kinase, can inhibit the classic 
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morphological characteristics of necrosis (50, 132). These studies provide evidence that 
necrosis is regulated and novel strategies to block necrosis could be developed. 
Necrotic cell death is associated with acute ischemic injury including myocardial 
ischemia, stroke, acute liver, kidney and lung injury, some of which are primarily due to 
MPTP formation (58).  Upon MPTP formation, cytoplasmic water and solutes ≤ 1.5 kD in 
size move osmotically into the mitochondrial matrix, resulting in organelle swelling and 
eventual rupture and catastrophic energy failure, key events in necrotic cell death (10).   
ROS and Calcium (Ca2+) increase the probability of opening the MPTP, whereas 
adenine nucleotides (i.e., ADP and ATP) inhibit pore formation (13, 43). Ca2+, the most 
noted mediator of permeability transition, enters the matrix via the mitochondrial calcium 
uniporter complex (MCU and MCUR1) driven by the highly negative membrane potential 
(Δψ). ROS increase MPTP open probability whereas ADP and ATP inhibit pore 
formation (13, 43). Various molecular components of the IMM and OMM have been 
proposed to form the large, nonselective MPTP, including Bax/Bak (84), F1/F0 ATP 
synthase (3, 12, 15), voltage-dependent anion channel (VDAC), adenine nucleotide 
translocator (ANT), and CypD (9, 55, 63, 64, 93), although recent evidences support 
participation of CypD, Bax/Bak and the F1/F0 ATP synthase and is discussed below. 
From the historical perspective, numerous molecular constituents of the MPTP, such 
as VDAC, ANT, and CypD, have been suggested as necessary for pore formation.  Only 
the involvement of CypD has been successfully verified by genetic deletion. Until fairly 
recently, the model for the pore, including the ANT in the IMM with the VDAC in the 
OMM together forming a continuous channel across the IMS under the control of CypD, 
is rejected by recent evidence. Genetic deletion studies showed that ANT and VDAC are 
dispensable for pore formation (9, 93).  
CypD is a mitochondrial matrix peptidyl-prolyl cis-trans isomerase and has an 
important role in controlling the opening of MPTPs (8). Convincing evidence obtained in 
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CypD-knockout mice suggests its relation to IRI in heart (129) and brain (140). Indeed, 
previous studies from our lab suggest that knockout of CypD can reduce renal IRI, 
mainly by reducing necrosis (34). 
The identity of the OMM components of the MPTP and whether they are under the 
control of CypD remains largely unknown. In a recent report, Whelan et al found that 
mitochondria isolated from Bax/Bak double-null mouse embryonic fibroblasts (MEFs) 
were resistant to swelling and loss of membrane potential [Δψ] in response to Ca2+ 
challenge, suggesting that Bax/Bak is a required component of MPTP (174). Karch et al. 
showed that loss of Bax/Bak reduced OMM permeability (MOMP) and conductance 
without altering inner membrane MPTP function, but resulting in resistance to 
mitochondrial calcium overload and necrotic cell death (84). This result indicates that 
Bax/Bak regulates necrotic cell death by modifying MOMP. Collectively, these data 
suggest that the MPTP is an IMM-regulated process, although in the absence of 
Bax/Bak the OMM resists swelling and prevents organelle rupture to prevent necrotic 
cell death (84). The precise role of Bax/Bak in regulating the MPTP and necrosis in IRI 
has not been well studied.  
A possible IMM component of the MPTP is the F1/F0 ATP synthase (Complex V) of 
the electron transport chain (15, 56).  F1/F0 ATP synthases can physically interact with 
CypD and have the capacity to form the permeability transition pore in a Ca2+ dependent 
manner (55). This binding also decreases the catalytic activity of ATP synthase, which 
can be restored by cyclosporine A (CsA), an inhibitor of CypD; however, the mechanism 
by which the F1/F0 ATP synthase transforms from a catalytic conformation into a 
channel is still under intense investigation. Interestingly, the conformational change also 
converts the F1/F0 ATP synthase from ATP provider into ATP hydrolase, which depletes 
ATP and leads to necrotic cell death. Together with the action of CypD, the conformation 
change of F1/F0 ATP synthase ensues, leading to persistent MPTP opening and 
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irreversible damage to the cells (3).  This hypothesis is in agreement with the role of 
Ca2+-induced swelling, which induces release of the c-subunit from the F1, whereas CsA 
and ADP blocked this release. 
PARP-1-mediated necrosis  
The highly conserved PARP family consists of 18 members (4).  PARP-1, the most 
studied member is an important nuclear enzyme that regulates protein functions by 
poly(ADP-ribosyl)ation and gene expression as a transcription cofactor (72). PARP-1 
catalyzes the transfer of ADP-ribose from nicotinamide adenine dinucleotide (NAD+) and 
conjugates poly(ADP-ribose) (PAR) onto various proteins as well as to PARP-1 itself, 
thus leading to a variety of physiologic processes including up- or down-regulation in 
protein function, conformational changes and promotion of protein-protein interactions 
(95, 96). Additionally, the role of PARP-1 as a transcriptional regulator is confirmed by 
genetic or pharmacological inhibition, demonstrating its influence on the expression of 
inflammatory genes including nuclear factor-κB (NFκB) (36, 69, 91), tumor necrosis 
factor-α (TNF-α) (25, 112), interleukin-1-β (IL1-β) (25), IL-6 (61, 112), ICAM-1 (61, 187), 
and toll like receptor 4 (TLR4) (187). Activation of PARP-1 is also required for DNA 
repair (68) and in the presence of DNA single- or double-strand breaks. PARP-1 
transfers the ADP-ribose moiety of NAD+ to various nuclear proteins and to PARP-1 
itself. Excessive activation of PARP-1, such as in the setting of IRI, can lead to glycolytic 
inhibition (35), depletion of NAD+, and consequent depletion of ATP (36).   Glycolysis is 
dependent on NAD+ and its depletion could lead to inhibition of ATP production through 
glucose metabolism. PARP-1 can also inhibit crucial enzymes in glucose metabolism, 
including glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (62) and glucose 
phosphatase (hexokinase) (5) via poly(ADP-ribosyl)ation. This will further exacerbate 
ATP depletion and impair cellular viability, particularly in cells that are highly dependent 
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on glycolysis.  Previous reports from our laboratory and others have demonstrated that 
PARP-1 inhibition or gene deletion is protective against ischemia-reperfusion (36, 124, 
193), diabetes (143), and ureteral obstruction (92). 
An alternative mechanism by which PARP-1-mediated cell death occurs is by 
parthanatos, where nuclear-to-mitochondrial translocation of PAR triggers translocation 
of apoptosis inducing factor (AIF) from mitochondria to nucleus. During translocation into 
the nucleus, AIF recruits an unidentified endonuclease, to mediate a caspase-
independent cell death by inducing chromatin condensation and fragmentation into large 
fragments (∼50 kb) (33) that are characteristic of parthanatos (45, 107). Despite the 
strong evidence for AIF-mediated cell death, the lack of AIF translocation in cell death 
models characterized by DNA damage and PARP also has been reported (44). These 
data demonstrate that parthanatos is dispensable in certain cell types or in response to 
certain cell death inducers, while it is the predominant pathway in other PARP-1-
dependent models of cell death, suggesting that parthanatos is context-dependent. 
Pharmacological inhibition or gene deletion of PARP-1 or knockout of PARP-1 can 
significantly reduce proximal tubule injury and preserve kidney function (124, 192). It is 
proposed that activation of PARP-1 not only depletes NAD+ and reduces ATP 
production to induce necrosis, but also modifies other molecules including p53 to 
facilitate necrosis. This notion is based on recent reports indicating that p53 can be 
poly(ADP-ribosyl)ated following DNA damage in neurons, which impacts p53 
transcriptional regulation (121, 145). As a transcriptional factor, p53 has broad effects on 
gene expression. It is not clear if the expression of PARP-1 is regulated by p53 after IRI.  
Expression and activation of p53 after IRI  
The transcription factor p53, which was first identified as a tumor suppressor, 
conducts many essential cell functions like halting cell cycle, senescence, promoting 
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apoptosis and regulating cell metabolism (165, 166). Several studies have investigated 
the role of p53 after IRI. Kelly et al. first showed that the expression of p53 is increased 
in the medulla after IRI, and inhibition of p53 can reduce renal injury (87, 88). Molitoris et 
al. showed that p53–targeted siRNA attenuates ischemic acute kidney injury (126); 
however, Dagher et al. showed that the p53 inhibitor pifithrin-α can actually increase 
long-term renal fibrosis after IRI (32, 126). One study even showed protective effects of 
p53 on the kidney function after IRI (152). These conflicting results may reflect different 
experiment protocols and, probably more importantly, the global inhibition of p53 in cells 
including inflammatory cells. The use of p53 knockout (p53 KO) mice with the p53 gene 
specifically deleted in the proximal tubules is needed to focus on the role of p53 in the 
proximal tubular damage after IRI.  
p53, glycolysis, and energy production 
Like PARP-1, p53 plays a major role in ATP depletion selectively in the S3 segments 
of the proximal tubule. p53 induces the expression and activation of Tp53-induced 
glycolysis and apoptosis regulator (TIGAR) selectively in proximal tubules after 
ischemia-reperfusion injury (90). The activation of TIGAR inhibits the rate-limiting, 
phosphofructokinase-1 activity and glucose 6-phosphate dehydrogenase activity (11, 59, 
90). Therefore, it makes the proximal tubules more susceptible to ischemia and cell 
death in the settings of severe IRI. Thus TIGAR activation, along with PARP activation 
(35), could be key mechanisms involved in the cellular regulation of selective inhibition of 
glycolysis in the ischemic kidney proximal tubules. 
p53, PARP-1 and CypD in necrotic cell death  
Although it has been shown that p53 levels are significantly increased in the medulla 
24 h after IRI (88), its contribution to necrotic cell death in the proximal tubule has not 
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been studied. Recently, it has been reported that p53 can interact with CypD and 
increases the opening of MPTP, thus inducing necrotic cell death (160); however, the 
authors found no alteration in Ca2+-dependent MPTP opening, which is arguably the 
most fundamental regulator of permeability transition, suggesting that this may not be 
the only mechanism in necrotic cell death. Recent findings that p53, PARP-1, Bax/Bid 
and CypD participate in necrotic cell death insinuate that integration of their signaling 
pathways may be required to elicit necrotic cell death; however, the physical interactions 
and contributions of these molecules to necrotic cell death remain undefined. Given the 
marked interest in pharmacologically targeting necrotic pathways in IRI, delineation of 
these pathways may provide key insights to our understanding of the pathophysiology of 
IRI and to develop novel therapeutic strategies.  
Necroptosis, MPTP-mediated necrosis and ferroptosis in AKI 
The signaling pathway of necroptosis has been reviewed in detail recently (116, 134, 
159). Briefly, necroptosis can be triggered by death receptors including TNF receptors 
(74, 164), stimulation of TLR (67, 81), signaling through interferon receptors (154), or 
recognition of intracellular viruses by DNA-dependent activator of interferon regulatory 
factors (157). These pathways can induce the association of RIPK1 and 3 via receptor-
interacting protein–homotypic interacting motif (RHIM) RHIM-RHIM domain interactions 
and phosphorylation of RIPK3, which leads to aggregation of phosphorylated RIPK3 and 
phosphorylation of mixed lineage kinase domain-like (MLKL) by RIPK3 (108). 
Necroptosis generally occurs only if pro-survival transcriptional and/or apoptotic 
pathways are compromised. Although the terminal executive machinery of necroptosis is 
not completely clear, it is proposed that phosphorylation exposes the N-terminal portion 
of MLKL (128) to induce plasma membrane rupture and necroptosis, with release of 
damage-associated molecular pattern molecules (DAMPs) (20, 24, 168). Thus, MLKL 
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appears to be a key necroptotic effector, but exactly how it disrupts membranes is still 
not understood (39). 
A contribution of necroptosis to ischemic injury in the kidney has been demonstrated 
by the protective effect of necrostatin-1 (Nec-1), which was considered as an inhibitor of 
RIPK1 (114).  A protective role for Nec-1 in cisplatin- and hypoxia-injured tubular cells 
(155, 189), was also reported. Similarly, RIPK3-deficient mice were also shown to be 
protected against ischemic and cisplatin-induced AKI (113). A recent study questions the 
specificity of Nec-1 because it might have off-target effects on ferroptosis (47). Deletion 
of fas-associated protein with death domain (FADD) or caspase-8 or Nec-1 inhibition 
failed to protect isolated renal tubules from hypoxic injury (118).  Similarly, the Nec-1 
mediated protective effect in cyclosporin-mediated tubular damage (131) or contrast-
mediated AKI (117) was not due to prevention of tubular cell death. These data suggest 
that the effect of genetic loss of RIPK3, or Nec-1 inhibition on reducing kidney ischemia-
reperfusion injury may not be due to loss of necroptosis (118). Because these data 
argue against necroptosis as the primary mode of regulated cell death in renal tubules, 
the role of necroptosis in the pathogenesis of AKI was not pursued in this project. 
Ferroptosis, a new type of cell death 
Ferroptosis is a recently identified new type of cell death. It is characterized by an 
iron-dependent accumulation of lipid peroxides in the cell membrane. Evidence that 
ferroptosis plays an important role in acute renal failure was demonstrated by Angeli et 
al. in glutathione peroxidase 4 (Gpx4)-deficient human renal proximal tubular epithelial 
cells (47). Gpx4 catalyzes the reduction of hydrogen peroxide, organic hydroperoxides, 
and lipid peroxides utilizing reduced glutathione (GSH) and protects against oxidative 
stress. Gpx4 knockdown rendered cells susceptible to ferroptosis-inducing agents, 
indicating a Gpx4 regulated anti-ferroptotic machinery in the cells (47).  In a recent study, 
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Linkermann et al. reported a significant role for iron-dependent ferroptosis in necrosis of 
renal tubules, in models of severe IRI and oxalate crystal-induced AKI (118). 
Pharmacological studies showed that the protective effects of the ferroptosis inhibitor 
ferrostatin (termed 16-86) are superior to Nec-1 and sanglifehrin A (SfA) (118).  These 
data suggest that at least three independent pathways of regulated necrosis may be 
involved in IRI-mediated organ damage (118). Further studies to reveal the role in the 
pathogenesis of AKI are needed, since these data suggest its involvement. p53 as a 
transcription factor has been reported to be a regulator of ferroptosis by controlling the 
expression of SLC7A11, a glutamate/cysteine carrier in the membrane, which facilitates 
the transportation of cysteine into the cell and defends against ROS production. 
Activation of p53 after IRI might down regulate SLC7A11 carrier to induce ferroptosis in 
the epithelial cells, a hypothesis tested in this project through use of double and single 
knockout mice.  
Therapeutic potentials targeting necrosis 
Based on what we know now, a crucial step of PARP-1-and CypD-induced necrotic 
cell death is calcium influx and mitochondrial dysfunction (4, 43, 86). Blocking those 
steps might stop the positive feedback loop, and increase the chance of cell survival. 
Because the calcium is transported into mitochondria through the MCU transporter, this 
molecule was considered as a target to block calcium influx into mitochondria; however, 
knockout of MCU in heart did not significantly reduce infarct size after ischemia-
reperfusion (120). It is possible that other mechanisms might be activated in the absence 
of MCU, for example ROS, which leads to the opening of MPTP.  
Blocking Bax/Bak does not prevent all types of cell death, because the ATP synthase 
can still form the pore across the inner membrane (12, 15, 84). The presence of pore 
formation by ATP synthase suggests that MPTP formation is a fundamental biological 
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process that is important for normal biological function. It is not clear if blocking this 
conformational change will reduce necrosis after IRI.  
CypD is another target that responds to calcium influx. It might be used to block 
calcium- or ROS-induced necrosis.  Some evidence suggests that CsA can decrease 
cardiac infarction after coronary artery blockage (70). Knockout of CypD can also protect 
kidney tubular cells from necrotic cell death after IRI (46). If, indeed, mitochondrial 
dysfunction is required for PARP-1-induced necrosis, then blocking CypD should at least 
partially prevent PARP-1-induced necrosis.  
Another possible therapeutic target is PARP-1 pathway. As mentioned above, this 
pathway involves multiple steps and molecules in a cascade fashion. Several PARP 
inhibitors have been used in laboratory studies including nicotinamide, benzamide, and 
newer imidazopyridine (4). The dilemma is that blocking PARP might impede DNA repair 
in the cell, although it can also reduce necrosis. In cancer therapy, those inhibitors are 
actually used to promote cell death, because of their action to block DNA repair 
machinery. Therefore, targeting PARP downstream molecules such as PAR, AIF, or 
endonuclease G might provide better results. For example, targeting the interaction 
between AIF and PAR or AIF and DNA might stop necrosis.  
The successful application of these necrosis inhibitors in treating brain or heart 
ischemic diseases makes them promising candidates for treating IRI.  Future studies will 
first need to assess the effectiveness of those drugs on the kidney function. Targeting 
the right segments of the nephrons that involved in the pathogenesis of IRI will be 
another challenge.  
Cross talk between defined necrotic pathways 
Attempts to integrate different types of necrotic cell death into a universal process 
have been made, yet it seems only some terminal changes overlapped (50, 85, 159). 
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Adding to this puzzle, injured cells will also manifest with a more necrotic cell death after 
inhibition of apoptotic pathways (50). How a cell chooses one type of cell death over the 
other is not well understand. One previous hypothesis is that inadequate energy 
production might be a reason why a cell falls into necrotic death rather than apoptosis, 
based on the observation that apoptosis consumes large amount of ATP, while necrosis 
is associated with mitochondrial dysfunction and energy depletion. If this hypothesis is 
true, then the status of mitochondria would be the crucial point deciding what type of cell 
death to develop. 
PARP-1 regulates gene expression as a transcriptional cofactor and functions via 
poly (ADP-ribosyl)ation (4). In the presence of single- or double-strand breaks in DNA, 
PARP-1 transfers the ADP-ribose moiety of NAD+ to various nuclear proteins and to 
itself. Excessive activation of PARP-1, like in the setting of IRI, can lead to depletion of 
NAD+ and consequent ATP depletion. A possible mechanism relates to the sustained 
rise in cytosolic free calcium (Ca2+) observed after ATP depletion (150). Uptake of Ca2+ 
by mitochondria as well as increased ROS levels in mitochondria during reperfusion 
triggers the opening of the MPTP, which requires a functional CypD.  
The interaction between p53 and PARP-1 has long been established. In senescent 
and apoptosis cells, PARP-1 interacts with p53 and enhances the activation of p53. In 
the setting of necrotic cell death, the regulation of these two molecules has not been well 
studied, although one study showed that p53 regulates a nonapoptotic cell death 
through regulating the activity of PARP-1 after ROS injury (127). This suggests that 
PARP-1-mediated necrosis might be the downstream mechanism of p53-induced 
necrosis, although the translocation of p53 into mitochondria after injury could be 
another explanation. The use of in vivo and in vitro experiments may reveal the possible 
mechanisms of p53-induced necrosis and its unique role in IRI. 
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Can mitochondria be the downstream of necroptosis? Necroptosis was considered 
as an important type of cell death in IRI. Following the inhibition of caspase 8, 
stimulation of death receptor will lead to RIP1 will interact with RIP3, which is interfered 
by necrostatin-1 (117, 155, 189). The complex of RIP1/RIP3 will further activate MLKL, 
although the downstream mechanism is not completely understood (114). The MPTP 
seems to be part of the downstream machinery. First, the Bax/Bak seems to be 
indispensable for this type of cell death. Second, deletion of CypD can partially protect 
cells from necroptosis (83, 123). In contrast to these observations, in kidney IRI blocking 
both pathways after IRI has additive protection, which suggests that CypD dependent 
cell death and necroptosis are possible two separate pathways (113). Although PARP-1 
was considered as the downstream target of RIP1/RIP3 complexes, recent evidences 
argue against this hypothesis (149). Inhibition of PARP-1 and its downstream effector 
molecules does not protect cells from TNF-induced necroptosis. Blocking TNF-induced 
necroptosis also does not prevent PARP-1-induced necrosis. All of this evidence 
suggests that PARP-1- or CypD-induced necrosis has an independent pathway other 
than necroptosis; however, the overlap between PARP-1- and CypD-induced necrosis is 
not well understood in the IRI setting.  
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Summary  
Although our knowledge about necrotic cell death increased significantly during the 
past several years, the contribution of different types of cell death to the pathogenesis of 
AKI is not fully understood. First, although previous studies revealed the involvement of 
p53 in the pathogenesis of IRI, the role of p53 in AKI is not clearly demonstrated. 
Conflicting results were seen in the literature (31, 32, 88, 126, 152, 180). A properly 
designed experiment with reliable p53 inhibition in the kidney is needed. Secondly, the 
mechanism of p53-induced necrosis is not fully understood. Although there is some 
evidence suggesting that p53 can translocate into mitochondria and induce the opening 
of MPTP, it has never been tested in the renal injury model. Thirdly, it is not clear if there 
are any connections between different cell death pathways. If mitochondrial dysfunction 
and energy deficiency are crucial for PARP-1-induced necrosis, will deletion of CypD 
add more protection to PARP-1 knockout mice to protect kidney from AKI? Double 
knockout of these two genes is needed to answer those questions. Similarly, both 
PARP-1 and p53 are activated upon DNA damage. Although the connection between 
these two molecules has long been recognized, the overlapping and distinctive functions 
of PARP-1 and p53 in IRI are not clear. It is not known if double knockout of these two 
genes has stronger protective effects against IRI compared with knockout of either 
individual gene. 
In this project, first we hypothesized that knockout of p53 in the proximal tubules 
protects the kidney from ischemic injury. Second, we explored the possible mechanisms 
for the p53-induced necrosis: 1). p53 translocates into mitochondria to induce the 
opening of MPTP; 2). p53 regulates the expression of PARP-1 and Bax, which induces 
necrosis after IRI; 3). By regulating the expression of SLC7A11, p53 induces ferroptosis 
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after IRI. Third, we tested if double knockout of PARP-1 and CypD or PARP-1 and p53 
additively or synergistically protects kidney from ischemic injury. 
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Figure 1: A schema of our hypothesis. 
Ischemia/reperfusion to the kidney parenchyma leads to many secondary effects 
including disruption of cellular energy metabolism, production of ROS, and DNA damage. 
These secondary effects lead to activation of the nuclear repair enzyme PARP-1 and the 
transcription factor p53. Further, activation of p53 can induce the expression of Bax, 
which facilitates the MOMP for necrosis. Activated PARP-1 rapidly depletes intracellular 
NAD+ and ATP, and simultaneously inhibits GAPDH, which reduces glycolytic capacity 
in proximal tubules. ROS and Ca2+ increase the probability of MPTP opening via 
activation of CypD. The mitochondrial translocation of p53 as a mechanism for p53-
induced necrosis is also tested in this study (see the dashed line). 
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CHAPTER 1: SPECIFIC DELETION OF p53 IN PROXIMAL TUBULE PREVENTS IRI 2 
 
Introduction 
AKI is a clinical syndrome characterized by a rapid decline in GFR over a period of 
hours to days, leading to retention of metabolic waste products and disrupted fluid, 
electrolyte, and acid-base balance (16). IRI, which results from compromised perfusion 
of renal tissues, is the leading cause of AKI (110, 111).  The persistent perfusion deficit 
in the medulla and limited anaerobic glycolytic capacity make the PT the most vulnerable 
tubular segment to ischemic injury (125, 162, 179). Pathologically, IRI is characterized 
by apoptotic/necrotic cell death and inflammation in the outer medulla, which are 
proportional to the severity of renal ischemia (87, 88). Pro- and anti-apoptotic signaling 
pathways in the proximal tubule cell are precisely regulated by essential factors such as 
p53, glycogen synthase kinase 3 beta and B-cell lymphoma 2 (BCL2) family proteins (26, 
76, 88, 185). Therefore, it is crucial to understand the roles of these molecules in 
regulating tubular cell apoptosis in the pathogenesis of IRI.  
The transcription factor p53, which was first identified as a tumor suppressor, 
performs many essential cell functions, such as halting the cell cycle, promoting 
senescence and apoptosis, and regulating cell metabolism (185). In response to various 
cell stresses and DNA damage, p53 is rapidly stabilized. Activated p53 controls the 
transcription of target genes that are usually key factors in cellular stress pathways (100). 
Classical models of p53 activation require three steps: stabilization, sequence-specific 
DNA binding, and transcription initiation through interaction with other transcription 
                                                          
2 Some of the materials presented in this chapter were previously published: Yuan Ying, 
Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted deletion 
of p53 in the proximal tubule prevents ischemic renal injury (183). 
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factors (100).  Although the transcriptional activation of p53 was considered the major 
mechanism by which p53 responds to cell stresses, several studies suggest that 
transcription-independent activity of p53 can potentiate apoptosis by directly interacting 
with members of BCL2 family proteins (28, 185). Recently, Angelina et al. reported that 
p53 interacts with CypD and increases the opening of the mitochondrial permeability 
transition pore, thereby inducing necrotic cell death (160). These findings suggest that 
p53 may have additional functions in the cytoplasm separate from its transcriptional 
activity. 
The involvement of p53 has been reported in nephrotoxic and ischemic renal injury 
(126, 170, 194). Although previous studies showed that p53 levels are significantly 
increased in the medulla 24 h after IRI (88), the contribution of p53 to tubular cell death 
and kidney dysfunction is still unclear. Further, global inhibition of p53 as a therapeutic 
strategy may not be feasible as it has a wide array of functions. Thus, considering the 
importance of p53 in promoting apoptotic/necrotic cell death, we hypothesized that 
knockout of p53 specifically in the proximal tubule significantly reduces tubular cell death 
and kidney dysfunction after IRI. This hypothesis was tested by using knockout mice 
with the p53 gene specifically deleted in the proximal tubule. 
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Methods 
Generation of PT-specific p53 knockout (PTp53 KO) mice and global p53 KO rats. 
Homozygous p53–floxed mice (C57BL/6J background) were obtained from Jackson 
Laboratories (Bar Harbor, ME). The breeding strategy for transgenic mice that 
expressed Cre recombinase under the control of kidney-specific Pepck promoter 
(Pepck-Cre) was reported elsewhere. KO mice with the p53 gene specifically disrupted 
in renal proximal tubular epithelial cells (genotype p53fl/fl, Cre+/-) were developed by 
mating p53-floxed mice (wild type, WT) with Pepck-Cre transgenic mice. A routine PCR 
protocol was used for genotyping from tail DNA samples with the following primer pairs: 
Cre, 5’-CGGTGCTAACCAGCGTTTTC -3’ and 5’- TGGGCGGCATGGTGCAAGTT -3’; 
and p53, 5’- GGTTAAACCCAGCTTGACCA -3’ and 5’- GGAGGCAGAGACAGTTGGGA 
G -3’. Male littermates of genotype p53fl/fl, Cre-/- were used as controls (WT). p53 KO 
rats (Tp53tm1(EGFP-Pac) QlyRrrc) were obtained from Rat Resource & Research Center, 
University of MO, Columbia, MO. All animals were born at the expected Mendelian 
frequency and did not display any gross physical or behavioral abnormalities. Animal 
experiments were approved by the Institutional Animal Care and Use Committee of the 
University of Nebraska Medical Center. 
Induction of IRI. IRI was induced in male mice as described previously (34-36). All 
animals were given free access to food and water. The mice were anesthetized by 
intraperitoneal administration of a cocktail containing ketamine (200 mg) and xylazine 
(16 mg) per kilogram of body weight. Ischemic injury was induced by bilateral renal 
pedicle clamping using microaneurysm clamps (Roboz Surgical Instrument, 
Gaithersburg, MD) and keeping mice core body temperature at 37℃. After 30 min of 
occlusion, the clamps were removed, and kidney reperfusion was verified visually. 
Sham-operated control animals underwent the same surgical procedure, except for the 
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occlusion of the renal arteries. During the surgery, all animals were placed on a heating 
pad to maintain body temperature at 37 ℃. Blood samples were collected at the time of 
sacrifice or from the orbital sinus under isoflurane anesthesia at 0, 6, 24 and 48 h post-
IRI for measurement of serum creatinine and BUN. Similarly, rats were also given 
bilateral renal pedicle clamping for 45 minutes before repression. At the end of each time 
point (1 d, 5 d or 16 d), renal tissue was collected, fixed in Bouins solution or snap frozen 
using liquid nitrogen, and stored at -80°C for future experiments. 
Measurement of plasma creatinine and BUN. Plasma creatinine and BUN were 
measured to evaluate renal function using a Quantichrom assay kit (BioAssay Systems, 
Hayward, CA) according to the manufacturer’s protocol. 
Morphological studies. Wild type and knockout mice that underwent IRI were 
sacrificed at 1 or 16 d. The kidneys then were processed at the University of Nebraska 
Medical Center histology core facility. Briefly, kidneys were fixed in formalin, embedded 
in paraffin, and cut into 5 μm sections. The tissue sections were then stained with 
Periodic acid-Schiff (PAS).  
Immunofluorescence for neutrophils. Formalin-fixed mouse kidney sections were 
processed for immunostaining as described previously (192). The slides were 
sequentially incubated with rabbit anti-mouse neutrophil antibody (Accurate, Westbury, 
NY) at a 1:100 dilution overnight at 4 ℃, followed by FITC-conjugated goat  anti-rabbit 
IgG (Vector Labs, Burlingame, CA) at a 1:200 dilution for 1 h at room temperature. 
Neutrophil infiltration was quantified by counting the number of stained cells per field. 
Immunohistochemistry for macrophages and phospho-Histone-3 (p-H3) staining. 
Formalin-fixed mouse kidney sections were processed for immunostaining by sequential 
incubation with rabbit anti-F4/80 antibody (18705-1-AP, Proteintech, Chicago, IL) and 
anti-p-H3 antibody (sc-8656-R, Santa Cruz, Santa Cruz, CA) at a 1:100 dilution 
overnight at 4 ℃, followed by HRP-conjugated goat anti-rabbit IgG (Vector Labs, 
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Burlingame, CA) at a 1:200 dilution for 1 h at room temperature. The color development 
was induced by diaminobenzamide reagent (Vector Labs, Burlingame, CA) according to 
the manufacturer’s instructions. Macrophage infiltration and p-H3 positive cells were 
quantified by counting the number of stained cells per field. 
Lipid hydroperoxide assays were performed in the kidney extracts using kits 
(BioVision, Mountain View, CA) according to manufacturer’s instructions. 
Apoptosis detection by TUNEL staining. TUNEL staining of kidney tissue sections 
was carried out using the In Situ Cell Death Detection kit, Fluorescein (Roche, 
Indianapolis, Indiana) according to manufacturer’s protocol. 
Collagen deposition by Sirius red. The rehydrated paraffin sections were stained with 
Sirius red solution (0.1% Direct Red 80 and 1.3% picric acid; Sigma, St. Louis, MO) and 
washed twice in acidified water (0.5% acetic acid; Sigma). Then, the sections were 
dehydrated and cleared before being observed under the microscope (92). 
α-smooth muscle actin (α-SMA) immunofluorescence staining. Formalin-fixed mouse 
kidney sections were processed for immunostaining as described previously (192). The 
slides were sequentially incubated with mouse anti-α-SMA antibody (A5228, Sigma) at a 
1:500 dilution overnight at 4 ℃, followed by FITC-conjugated horse anti-mouse IgG 
(Vector Labs) at a 1:200 dilution for 1 h at room temperature. α-SMA deposition was 
quantified by measuring α-SMA positive area per field. 
Western blot analysis. Briefly, whole renal tissue extracts (80 μg protein/lane) were 
separated on 10% SDS-PAGE gels and then transferred to Immobilon membranes 
(Millipore, Bedford, MA). The membranes were incubated with anti-p53 (2524, Cell 
Signaling, Beverly, MA), anti-p21 (sc-6246, Santa Cruz, Santa Cruz, CA), anti-activated 
Bax (sc-23959, Santa Cruz), anti-cleaved caspase-3 (9664, Cell Signaling), anti-Bid 
(611866, BD bioscience, San Jose, CA), anti-Siva (sc-48768, Santa Cruz), anti-α-SMA 
(A5228, Sigma), anti-p-Smad3 (ab51451, Abcam Cambridge, MA), anti-phospho-
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Ser/Thr-Pro, MPM-2 antibody (05-368, Millipore) and anti-GAPDH (sc-25778, Santa 
Cruz) antibodies overnight at 4°C. After washing, the membranes were incubated with 
horseradish peroxidase-conjugated secondary antibodies against the appropriate 
primary antibodies (1:5,000, Vector Laboratories, Burlingame, CA), exposed to Western 
Lighting Plus-ECL (NEL104001EA; PerkinElmer, Waltham, MA), and then developed 
with X-ray film. The area of each band was analyzed using NIH image software (Image 
J). For quantification, band densities were measured using ImageJ. The relative 
densities were measured by dividing the density of target protein by the density of 
loading control (GAPDH) for the same lane. Then the fold changes were calculated by 
dividing each of the relative densities of target protein by the relative density of WT-
sham. When only two lanes were used for comparison, the variability of the relative 
density of control group was calculated by normalizing the individual values of the 
controls to the mean of the control group.  
Proximal tubular cell culture and in vitro experiment. Primary proximal tubule 
epithelial cells were isolated from PTp53 KO or WT male mice and cultured as described 
previously (35, 66). The porcine-derived proximal tubular cell line LLC-PK1 (ATCC, 
Rockville, MD) was cultured to 80 to 90% confluent monolayer cultures as described 
previously (136). The cells were incubated with 1, 2 or 5 mM H2O2 for 1 h to induce 
necrosis (127). These concentrations and times were chosen for trypan blue staining as 
previously described (35, 113). Pifithrin-α at different concentrations was administered in 
the culture media 30 min before injury. Lactate dehydrogenase (LDH) release was 
measured enzymatically using a CytoTox 96® Non-Radioactive Cytotoxicity Assay kit 
(Promega, Madison, WI). 
Statistics. All data are expressed as means ± SE. Two-way and one-way ANOVA 
were used to compare the mean values of all groups, followed by Tukey's multiple 
comparison test to compare the mean values between two groups. An unpaired t-test 
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was also used to compare the means of two different groups. A P value < 0.05 was 
considered statistically significant. 
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Results 
Deletion of p53 in the proximal tubule reduces p53 expression after IRI. We analyzed 
the expression of p53 and one of its target genes, p21, after injury in whole kidney 
tissues. Indeed, 24 h after IRI, the expression of p53 (Fig. 2A, B) and p21 (Fig. 2A, C) 
was significantly increased in WT male littermates to that in sham-operated mice 
kidneys. However, the expression level of p53 was only slightly increased and p21 
expression was not altered in PTp53 KO mice after IRI compared to that in sham-
operated mice kidneys. The slightly increased levels of p53 in IRI-induced PTp53 KO 
may be due to p53 expression in cells other than the PT.  Due to the difficulty in 
detection of p53 in renal tissue, we carried out Western blot analysis for p53 in PT 
isolated from PTp53 KO mice.  Our data further confirmed successful deletion of p53 in 
the PT (Fig. 3). These data suggest that p53 is induced and is involved in transcriptional 
regulation after IRI. 
PT-specific knockout of p53 reduced deterioration of renal function after IRI. To test 
whether the absence of p53 in the PT changes the course of IRI, kidney function after 
IRI in PTp53 KO mice and in WT littermates was assessed. BUN levels were increased 
in WT mice 6 h after IRI and peaked during 24 - 48 h compared with WT sham-operated 
mice. The increase in BUN level was significantly less in PTp53 KO mice 6 - 48 h after 
IRI compared with WT mice (Fig. 4A). Plasma creatinine levels were also increased in 
WT mice 6 - 48 h after IRI compared with WT sham-operated mice. Similar to the BUN 
levels, the increase of plasma creatinine was less in PTp53 KO compared with WT at 6, 
24, and 48 h after IRI (Fig. 4B). No significant difference in renal function occurred 
among sham-operated WT and KO mice (Fig. 4A and B). Moreover, there were no 
significant differences in BUN or plasma creatinine values between WT and 
heterozygous mice after IRI (data not shown). These data suggest that specific deletion 
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of the p53 gene in the proximal tubule leads to renal functional protection after IRI in 
mice. 
PT-specific knockout of p53 decreased renal histological damage after IRI.  Ischemic 
kidneys from WT mice showed widespread necrosis, brush border blebbing, and 
sloughed cells in the proximal straight tubule, whereas these features were much less 
apparent in ischemic kidneys from PTp53 KO mice. The histological changes after IRI 
were quantified by counting and scoring the percentage of tubules that displayed tubular 
necrosis, cast formation, and tubular dilation (Fig. 5A, B). The cumulative score of 
histological damage in the outer medulla at 1, 5 and 16 days as well as necrosis at 1 d 
(Fig 5C) was significantly lower in PTp53 KO kidneys compared with WT kidneys post-
IRI, demonstrating that gene ablation of p53 reduced tubular damage and cellular 
necrosis.  
Renal inflammation was reduced after IRI in PTp53 KO mice. The infiltration of 
leukocytes in the outer medulla of WT and PTp53 KO mice at 1, 5 and 16 days post-IRI 
was assessed by immunostaining for neutrophils and macrophages. As shown in 
representative photographs (Fig 6A and 7A), WT mice exhibited increased infiltration of 
neutrophils and macrophages in the outer medulla, which was attenuated in PTp53 KO 
mice. The numbers of positively stained cells were counted in a blinded manner and 
quantitative data indicate that the accumulation of neutrophils and macrophages was 
reduced in the outer medulla of PTp53 KO mice compared to that of WT mice at all-time 
points after IRI (Fig. 6B and 7B). 
Attenuated oxidative stress after IRI in PTp53 KO mice.  Oxidative stress was 
assessed by lipid hydroperoxide levels in the kidney.  Quantification of the whole kidney 
lipid peroxide levels at 5h, 1 and 2 days post-IRI demonstrates that  its levels were 
significantly decreased in PTp53 KO mice compared to that of WT mice at all time points 
(Fig 8A).   
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PT-Specific deletion of p53 decreased PARP-1 expression after IRI. PARP-1 can 
induce necrotic cell death after IRI.  PARP-1 expression was examined by Western blot 
analysis.  PARP-1 expression was significantly increased in WT kidneys after IRI but its 
expression was downregulated in PTp53 KO mice (Fig 8B).  This novel finding suggests 
that increased PARP-1 function may be one of the mechanisms by which p53 activation 
regulates necrosis. 
PT-specific KO of p53 decreased apoptosis after IRI. To determine whether there is 
a change of apoptotic levels in the outer medulla of WT mice compared with PTp53 KO 
mice, TUNEL assay was performed together with Western blot analysis for pro-apoptotic 
proteins. The outer medulla of wild type mice exhibited increased numbers of TUNEL-
positive cells compared with that of PTp53 KO mice (Fig. 9). Cleaved caspase-3 
expression was increased in WT kidney 24 h after IRI compared with p53 KO mice (Fig 
10A, B) further confirming increased apoptosis. Similarly, Western blot analysis showed 
enhanced activation of Bax in the kidney of wild type mice compared with that of PTp53 
KO mice 24 h after IRI, while total Bax was not changed. The expression of pro-
apoptotic proteins Bid and Siva was also increased in WT mice after IRI in compared to 
PTp53 KO mice (Fig. 10A, C-E). These data suggest that specific deletion of p53 in the 
proximal tubule decreases apoptotic cell death after IRI by decreasing the levels of pro-
apoptotic proteins. 
Loss of p53 reduced renal fibrosis after IRI. To investigate whether deletion of p53 
reduces renal fibrosis, collagen deposition in the kidneys of WT and PTp53 KO mice 
was measured using Sirius red staining and α-SMA immunofluorescence staining. 
Sixteen days after IRI, WT mice showed a dramatic increase of Sirius red-positive area 
in the kidneys compared with PTp53 KO mice, indicating that deletion of p53 reduces 
renal fibrosis in the later stage of IRI (Fig. 11A, B). No change in the Sirius red staining 
was seen at 5 d post-injury.  α-SMA expression, on the other hand,  was decreased in 
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PTp53 KO mice compared with WT mice at 5 after IRI, as demonstrated by 
immunostaining and Western blot analysis (Fig. 11C, D). p-Smad3, a downstream 
signaling molecule of TGFβ, was also increased in wild type mice, but significantly 
reduced in PTp53 KO mice at 16 d post-IRI (Fig. 12).  
Loss of p53 reduced cell cycle arrest after IRI. Cell cycle arrest at G2/M phase is 
associated with late kidney fibrosis in ischemic renal injury. Histone H3 is 
phosphorylated during mitosis at Ser-10 in the G2/M phase (142). p-H3 staining was 
performed to detect G2/M phase arrest. In wild type mice, the number of p-H3 positive 
cells was significantly higher compared with PTp53 KO mice at 1, 5 and 16 d after IRI 
(Fig. 13). To confirm that the cells are truly arrested at the G2 phase and not in mitotic 
phase, we assessed the number of mitotic cells at the above time points. Mitotic entry is 
accompanied by the phosphorylation of several molecules including MPM-2 (mitotic 
protein monoclonal 2) that may regulate the mitotic processes (101, 173).  
Immunostaining using anti-phospho-Ser/Thr-Pro, MPM-2 antibody (05-368, millipore) 
demonstrated that the number of cells at M phase was increased in WT mice 1 d after 
IRI compared with KO mice, but it only accounted for a small fraction of cells arrested at 
G2/M phase, indicating that most p-H3 positive cells were arrested at G2 phase (Fig. 
14).  The number of cells at M phase was negligible at 5 and 16 d in both WT and PTp53 
KO mice tissues. 
Loss of p53 reduced necrotic cell death of PTC. To further study the role of p53 in 
necrotic cell death, we used an in vitro H2O2-induced necrosis model.  Necrosis was 
assayed using trypan blue staining and lactate dehydrogenase (LDH) release assay. 
After 1 h treatment with 1 or 2 mM H2O2, PTp53 KO primary PTC had less trypan blue-
positive cells than WT PTC (Figure 15A). Pharmacological inhibition of p53 using 
pifithrin-α also reduced LDH release in LLC-PK1 cells after 5 mM H2O2 treatment (Figure 
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15B). These data indicate that deletion or inhibition of p53 reduces H2O2–induced 
necrosis. 
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Figure 2: p53 and p21 expression in p53 WT and PTp53 KO mice after IRI. 
(A) Representative images of Western blot analysis showing expression levels of p53 
and p21 at 24 h after IRI. (B, C) The expression levels of p53 and p21 in sham and IRI-
induced kidneys were quantified (n = 4 in each group). * P < 0.05 compared with WT-IRI; 
† P < 0.05 compared with WT-Sham. GAPDH served as a loading control (183).  
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Figure 3: Western blot showing p53 levels in proximal tubules of WT and PTp53 KO 
mice before IRI.  
* P < 0.05 compared with WT, n = 4 (183).  
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Figure 4: Kidney function in p53 WT and KO mice after IRI. 
(A) Plasma creatinine and (B) BUN levels from WT and PT p53 KO mice (n = 6) at 6 h, 1 
d, 2 d and 3 d after IRI. * P < 0.05 compared with WT-IRI; † P < 0.05 compared with WT-
Sham (183).   
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Figure 5: Kidney histological changes in p53 WT and PTp53 KO mice after IRI. 
(A) WT or PTp53 KO mice underwent sham surgery or IRI.  Renal histological changes 
in the outer medulla after IRI were assessed by PAS staining at 1, 5 and 16 d after IRI. 
Magnification is 400×. (B) Histological damage in the outer medulla assessed in PAS-
stained kidney sections was scored by counting the percentage of tubules that displayed 
tubular necrosis, cast formation, and tubular dilation as follows: 0 = normal; 1 = < 10%; 2 
= 10–25%; 3 = 26–50%; 4 = 51–75%; and 5 = > 75%. Ten fields (200× magnification) 
per kidney were used for counting. (C) The number of necrotic tubules was counted in 
PAS-stained kidney sections at 1 d after IRI. *P < 0.05 compared with WT-IRI; † P < 
0.05 compared with Sham (same genotype); n = 6 (183).  
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Figure 6: Neutrophils infiltration in the kidney after IRI. 
(A) Typical neutrophil accumulation in the outer medulla of WT and PTp53 KO kidneys 
at 1, 5 and 16 d post IRI. Neutrophils (PMN) were identified by immunofluorescence 
using a neutrophil-specific antibody. Number of neutrophils (B) accumulation in the outer 
medulla of WT and p53 KO kidneys post-IRI was measured at 1, 5 and 16 d after IRI in 
high magnification (200×) fields. * P < 0.05 compared with WT-IRI; † P < 0.05 compared 
with WT-Sham; n = 4 (183).   
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Figure 7: Macrophages infiltration in the kidney after IRI. 
(A) Typical macrophage accumulation in the outer medulla of WT and PTp53 KO 
kidneys at 1, 5 and 16 d post IRI. Macrophages were identified by DAB staining using 
anti-F4/80 antibody. Images are representative of four independent experiments. 
Number of macrophages (B) accumulation in the outer medulla of WT and p53 KO 
kidneys post-IRI was measured at 1, 5 and 16 d after IRI in high magnification (200×) 
fields. * P < 0.05 compared with WT-IRI; † P < 0.05 compared with Sham (same 
genotype); n = 4 (183).   
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Figure 8: Lipid hydroperoxide levels and PARP-1 expresion in the WT and PTp53 KO 
mice after IRI. 
(A) Lipid hydroperoxide levels in the WT and PTp53 KO mice after IRI. *P < .05 
compared with WT-IRI; n = 6. (B) Western blots showing increased expression of PARP-
1 24 h after IRI in WT kidneys. * P < 0.05 compared with WT-IRI; † P < 0.05 compared 
with WT-Sham; n = 3 (183). 
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Figure 9: TUNEL staining for apoptosis after IRI. 
(A) Apoptosis detection by TUNEL staining in WT and PTp53 KO kidneys at 1, 5 and 16 
d post IRI. Images are representative of four independent experiments. (B) TUNEL 
assay to detect apoptotic cells was done using the In Situ Cell death detection kit in 
kidneys derived from WT or PTp53 KO at 1, 5 and 16 d after IRI.  Number of TUNEL 
positive cells was measured in 10 randomly chosen high magnification (200×) fields per 
kidney. * P < 0.05 compared with WT-IRI; † P < 0.05 compared with WT-Sham; n = 5 
(183).  
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Figure 10: The expression of apoptotic molecules after IRI. 
(A-E) Representative Western blots images showing increased expression of cleaved 
Caspase-3, Bax, Bid, and Siva in WT and PTp53 KO mice after 24 h IRI. * P < 0.05 
compared with WT-IRI; † P < 0.05 compared with WT-Sham; n = 3-5 (183).  
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Figure 11: Kidney fibrosis in WT and PTp53 KO kidneys after IRI. 
(A) Collagen deposition detected by Sirius red staining in WT and PTp53 KO kidneys at 
5 and 16 d after IRI; (B) The Sirius red-positive area was measured in four randomly 
chosen high power (200×) fields per kidney using the NIH Image J software. (C, D) 
Immunofluorescence staining of α-SMA in outer medulla. The α-SMA -positive area was 
measured in four randomly chosen high power (200×) fields per kidney. * P < 0.05 
compared with WT-IRI; † P < 0.05 compared with Sham (same genotype); n = 4 (183).   
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Figure 12: The expression of α-SMA and p-Smad3 in WT and PTp53 KO kidneys after 
IRI. 
(A, B) Representative Western blot images and quantified data for expression of α-SMA 
in WT and PTp53 KO kidneys at 1, 5, and 16 d after IRI. (A, C) Representative Western 
blots films and quantified data for expression of p-Smad3 in WT and PTp53 KO kidneys 
at 1, 5, and 16 d after IRI. * P < 0.05 compared with WT-IRI; † P < 0.05 compared with 
Sham (same genotype); n = 3. GAPDH served as a loading control (183).   
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Figure 13: Cell cycle arrest at G2/M phase after IRI. 
(A) Cell cycle arrest at G2/M phase was analyzed by p-H3 staining.  Representative 
images of p-H3 staining in WT and PTp53 KO kidneys at 1, 5 and 16 d after IRI. Images 
are representative of five independent experiments. (B) Number of p-H3 positive cells in 
WT and PTp53 KO kidneys at 1, 5, and 16 d after IRI was counted in 10 randomly 
selected high power (200×) fields per kidney. * P < 0.05 compared with WT-IRI; † P < 
0.05 compared with WT-Sham; n = 4 (183).  
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Figure 14: Cells arrested at M phase after IRI in WT and PTp53 KO kidneys. 
 (A, B) Cells at M phase were marked by anti-phospho-Ser/Thr-Pro MPM-2 antibodies. * 
P < 0.05 compared with WT-IRI 1 d; † P < 0.05 compared with WT-Sham; n = 4 (183).  
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Figure 15: The protective effects of p53 deletion or inhibition on necrosis in vitro.  
(A) Percentage of trypan blue positive cells after H2O2 treatment in primary PTC derived 
from PTp53 KO compared with WT mice cells. * P < 0.05 compared with WT-H2O2 
treatment; † P < 0.05 compared with WT-control; n = 4. (B) Percentage of LDH activity 
after 5 mM H2O2 treatment in LLC-PK1 cells with or without different concentrations of 
the p53 inhibitor pifithrin-α. * P < 0.05 compared with H2O2 treatment alone; † P < 0.05 
compared with control; n = 4 (183).  
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Global knockout of p53 in rats did not protect renal function after IRI. To test whether 
the absence of p53 in the whole kidney protects kidney function after IRI in p53 KO rats 
and in WT littermates, BUN levels were increased in WT rats 24 h after IRI compared 
with WT sham-operated rats. p53 KO and heterozygous rats had similar levels of BUN  
24 h after IRI compared with WT rats (Fig. 16). Plasma creatinine levels were also 
increased in WT rats 24 h after IRI compared with WT sham-operated rats. Similar to the 
BUN levels, p53 KO and heterozygous rats had comparable levels of creatinine 24 h 
after IRI compared with WT rats (Fig. 16). These data suggest that global deletion of the 
p53 gene does not lead to renal functional protection after IRI in rats. 
Global knockout of p53 in rats did not decrease renal histological damage after IRI.  
Ischemic kidneys from WT rats showed widespread necrosis, brush border blebbing, 
and sloughed cells in the proximal straight tubule. Similar features were observed in 
ischemic kidneys from p53 KO rats. The histological changes after IRI were quantified by 
counting and scoring the percentage of tubules that displayed tubular necrosis, cast 
formation, and tubular dilation (Fig. 17). The cumulative score of histological damage in 
the outer medulla at 1 d was similar between p53 KO kidneys and WT kidneys post-IRI, 
demonstrating that global gene ablation of p53 in kidney does not reduce tubular 
damage.  
Global knockout of p53 in rats had decreased apoptosis after IRI. To determine 
whether there is a change of apoptotic levels in the outer medulla of WT rats compared 
with p53 KO rats, TUNEL assay was performed. The outer medulla of wild type rats 
exhibited increased numbers of TUNEL-positive cells compared with that of p53 KO rats 
(Fig. 18). These data suggest that global deletion of p53 in the kidney decreases 
apoptotic cell death after IRI. 
Loss of p53 did not reduce renal fibrosis after IRI. To investigate whether global 
deletion of p53 reduces renal fibrosis, collagen deposition in the kidneys of WT and p53 
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KO rats was measured using Sirius red staining and α-SMA immunofluorescence 
staining. Sixteen days after IRI, p53 KO rats showed a dramatic increase of Sirius red-
positive area in the kidneys similar to WT rats, indicating that global deletion of p53 does 
not reduce renal fibrosis in the later stage of IRI in rats (Fig. 19).  α-SMA expression was 
not decreased in p53 KO rats compared with WT rats at 16 days after IRI, as 
demonstrated by immunostaining and Western blot analysis (Fig. 20).  
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Figure 16: Kidney function in p53 WT or global KO rats after IRI. 
Plasma creatinine (A) and BUN (B) levels from WT, p53 heterozygous (HZ) and global 
p53 KO rats (n = 5) at 1 d after IRI. † P < 0.05 compared with Sham.  
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Figure 17: The kidney histological changes in p53 WT and global p53 KO rats after IRI. 
Renal histological changes in the outer medulla after IRI were assessed by PAS staining 
at 1 d after IRI. Magnification is 400×. Histological damage in the outer medulla 
assessed in PAS-stained kidney sections was scored by counting the percentage of 
tubules that displayed tubular necrosis, cast formation, and tubular dilation as follows: 0 
= normal; 1 = < 10%; 2 = 10–25%; 3 = 26–50%; 4 = 51–75%; and 5 = > 75%. Ten fields 
(200× magnification) per kidney were used for counting, † P < 0.05 compared with Sham, 
n = 6.   
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Figure 18: TUNEL staining in p53 WT and global p53 KO kidneys after IRI. 
Apoptosis detection by TUNEL staining in WT and p53 KO kidneys at 24 hours post IRI. 
Images are representative of four independent experiments. Number of TUNEL positive 
cells was measured in 10 randomly chosen high magnification (200×) fields per kidney. * 
P < 0.05 compared with WT-IRI; † P < 0.05 compared with Sham; n = 6. 
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Figure 19: Collagen deposition after IRI in p53 WT and global p53 KO rats. 
Collagen deposition detected by Sirius red staining in WT and p53 KO kidneys at 16 d 
after IRI; (B) The Sirius red-positive area was measured in four randomly chosen high 
power (200×) fields per kidney using the NIH Image J software. † P < 0.05 compared 
with Sham.  
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Figure 20: α-SMA staining in WT and global p53 KO rats after IRI. 
Immunofluorescence staining and western blot of α-SMA in outer medulla. The α-SMA-
positive area was measured in four randomly chosen high power (200×) fields per kidney. 
† P < 0.05 compared with Sham.  
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Discussion 
Ischemic renal injury is strongly associated with proximal tubular cell necrosis and 
apoptosis (71). It has been shown that interference with many cell death mediators 
provides protective effects on renal function (76, 87, 88). Among these molecules, p53 
has gained particular attention because of its key role in senescence, apoptosis and 
even necrosis (166). Indeed, our studies show that specific knock out of p53 gene in the 
proximal tubule significantly improves kidney function and reduces apoptosis after IRI, 
along with attenuated inflammatory response and long-term fibrosis. These findings 
support the concept that p53 is a critical mediator of apoptosis after IRI. 
Several studies have investigated the role of p53 in IRI. Kelly et al. first showed that 
p53 expression is increased in the renal medulla after IRI (88), and inhibition of p53 can 
reduce renal injury in rats. Molitoris et al. showed that systemic administration of p53-
targeted siRNA into mice attenuates ischemic acute kidney injury (126). However, 
Dagher et al. showed that the p53 inhibitor pifithrin-α can actually increase long-term 
renal fibrosis after IRI (32), and Sutton et al. showed that global p53 deficiency 
exacerbates injury (152). These conflicting results may reflect different experimental 
protocols and, probably more importantly, differing effects of global inhibition of p53 in 
cells within the kidney. This controversy suggests that the role of p53 in the 
pathophysiology of IRI is much more complicated and incompletely understood.  
In this study, we used knockout mice with p53 gene specifically deleted in the 
proximal tubule to study its effect on the kidney damage after IRI. This strategy not only 
specifically targets the proximal tubule, the major injury site of IRI (162), but also 
excludes the normal function of p53 in other cells within the kidney, like inflammatory 
cells recruited after IRI, in which absence of p53 may prolong inflammatory responses 
and increase renal injury. The deletion of p53 in the proximal tubule not only significantly 
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reduces apoptotic cell death in the outer medulla, but also preserves tubular architecture. 
Although the exact mechanisms by which reduced tubular cell damage preserves renal 
function are not fully understood, a possible explanation is that the maintenance of 
structural integrity reduces tubular cell shedding and cast formation in the later segments 
of nephrons, and thus mitigates tubular obstruction and preserves kidney function. Our 
studies in knockout mice also show reduced inflammatory responses and fibrosis, which 
may be the consequences of decreased cell death within the kidney. 
It is well established that p53 is known as “the guardian of the genome”, and mutated 
p53 frequently exists in many forms of tumors (166). This indicates that p53 is important 
for the regulation of cell proliferation and cell death. The regulation of p53 involves 
interactions with mouse double minute 2 homolog (MDM2), resulting in alterations in p53 
protein levels (100). Protein modifications like phosphorylation and acetylation are also 
important for the activation of p53 (100). Hypoxia-induced DNA damage by reactive 
oxygen species may contribute to activation of p53 and lead to p53-induced apoptosis 
(65). Thus, the p53 pathways have been broadly investigated in the emergence and 
progression of ischemic injuries. The role of p53 in mediating cell death in ischemic 
neuronal injury is well established, but is not well understood in ischemic renal injury (75).  
The effects of p53 activation after IRI involve changes in transcriptional activity and 
transcription independent functions (100, 166). First, the downregulation of p21, one of 
the major transcriptional products of p53 (41, 42), in knockout mice is expected, 
indicating increased selected transcription induced by p53. Although p21 is considered 
more as a cell cycle regulator than an apoptotic modulator (19, 42), activation of p21 by 
p53 may contribute to reduced cell proliferation after injury, thus restoring tubular 
structure. Second, an increased level of activated Bax without an increase in total Bax 
suggests that p53 induces Bax activation independent of transcription (28).  
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The MOMP is required for the execution of necrotic cell death as it forms part of 
MPTP.  Although Bax and Bak were considered as proapoptotic molecules, emerging 
evidence clearly demonstrate that Bax and Bak are integral components of the MOMP of 
the MPTP (185).  p53 can control the MOMP by (1) regulating the expression and 
function of Bax and Bid at the transcriptional level (28); (2) direct interaction with pro-
apoptotic Bax/Bak  and anti-apoptotic Bcl2 to modulate the pore activity (185) and (3) 
suppressing Bcl2 expression via activation of microRNAs (21, 153). However, the role of 
p53 in regulating Bcl2 family members to elicit necrosis remains undefined.    
As discussed earlier, Bax/Bak in their non-oligomerized form induced a low level of 
permeability of the outer mitochondrial membrane that is distinct from its mode of 
releasing cytochrome c in apoptosis, and permits necrosis through the MPTP (84).  A 
recent study also showed that p53 can translocate to mitochondria to interact with CypD 
and induce the opening of MPTP regardless of Bax/Bak activated MOMP (1). However, 
our data demonstrated that the significant decrease in necrosis in PTp53 KO ischemic 
kidneys is possibly through diminished expression of PARP-1, Bax and Bid.   
Recently, Vaseva et al. showed that p53 may also be implicated in necrotic cell 
death through its interaction with CypD in the inner membrane of mitochondria, and 
subsequent opening of mitochondrial permeability transition pores (160). However, it is 
still unknown how this in vitro finding can be translated into in vivo IRI models. Indeed, 
our data showed significantly reduced tubular cell necrosis in the outer medulla of PTp53 
KO mice in contrast to WT mice after IRI (Fig. 2). It is possible that mitochondrial 
translocation of p53 after IRI contributes to necrotic cell death rather than apoptotic cell 
death. Further studies may be needed to clarify this point. 
Studies from other groups verified the importance of having p53 deleted only in the 
proximal tubules (152, 188). Sutton et al. first showed that global p53 deficiency or 
pharmacological inhibition of p53 increases and prolongs leukocyte infiltration into the 
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renal parenchyma, which exacerbates renal injury after IRI. Another study from Zhang et 
al. showed that PTp53 knockout mice were protected from IRI, while mice with p53 gene 
knockout in other segments were sensitive to IRI (188). Indeed, our data from p53 global 
knockout rats showed that those rats had similar sensitivity to IRI and developed long 
term fibrosis similar to wild type rats, although p53 KO rats had reduced level of TUNEL 
positive cells. Those data suggest that the p53 gene in non-PT cells is also crucial for 
preserving the kidney function after IRI, possibly through a reduced inflammatory 
reaction when p53 function is intact in non-PT cells (152).  
In summary, this study shows p53 has strong effects on tubular cell death after IRI 
that can determine the final outcome of injury. Absence of p53 in the proximal tubule 
significantly preserves renal function and markedly reduces kidney damage, 
inflammation, and long-term fibrosis. Targeting proximal tubular cell death may provide a 
more efficient therapeutic strategy that may change the outcomes of IRI.  
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CHAPTER 2: THE MECHANISM OF p53-INDUCED CELL DEATH3  
 
Introduction  
The tumor suppressor protein p53 is a stress-responsive transcription factor because 
of its ability to activate multiple target genes in response to diverse stress conditions, 
including oxidative stress, genotoxic damage, oncogene activation, and hypoxia.  These 
p53 targets have prominent biological functions including cell cycle arrest, apoptosis, 
senescence, metabolism, and autophagy modulation (57). Moreover, recent evidence 
suggests that p53 also exists in cytoplasm, directly interacts with multiple cytoplasmic 
proteins, and modifies their activity (166). In addition, recent studies revealed a role for 
p53 in regulating necrotic cell death by inducing the opening of MPTP, and altering 
mitochondrial dynamics (28, 160).  Our in vivo and in vitro data from chapter 1 also 
support that idea that p53 plays a role in mediating necrotic cell death in PT.  Further 
understanding the mechanism of p53-induced necrosis is needed. 
The MOMP is required for the execution of necrotic cell death as it is part of MPTP.  
Although Bax and Bak are widely considered to be proapoptotic molecules, emerging 
evidence clearly demonstrate that Bax and Bak are integral components of the MOMP of 
the MPTP.  Recent studies, however, showed that p53 can translocate to mitochondria 
to interact with CypD and induce the opening of MPTP regardless of Bax/Bak activated 
MOMP (84, 86). This study emphasized the importance of p53-CypD interaction in the 
necrosis, which seems to be independent of MOMP. This is a possible explanation for 
the decreased necrotic tubules in the kidney after p53 deletion. So we first hypothesized 
                                                          
3 Some of the materials presented in this chapter were previously published: 1. Yuan 
Ying, Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted 
deletion of p53 in the proximal tubule prevents ischemic renal injury (183). 2. Yuan Ying 
and Babu J. Padanilam, Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D 
-overlapping pathways of regulated necrosis? (184) 
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that p53 translocates into mitochondria to induce the opening of MPTP, which leads to 
necrosis after IRI.  
A reciprocal regulation of PARP-1 by p53 was described by Montero et al. in ROS-
induced cell death (127).  Genetic deletion of p53 in MEFs, human breast or colorectal 
cancer cells conferred increased resistance to ROS and PARP-mediated necrotic cell 
death (127).  PARP activity at baseline and after ROS stimulation was reduced in the 
absence of p53. The mechanism by which p53 regulates PARP-1 activation and 
necrosis, in the setting of ROS-induced DNA damage, remains to be defined.   
Interestingly, inhibition of PARP-1-mediated necrosis led to p53-mediated caspase 
activation and apoptosis, indicating that PARP-1-mediated necrosis might be a 
downstream pathway of p53 signaling. Our data in chapter 1 demonstrated significant 
decreases in necrosis in p53 KO ischemic kidneys accompanied by decreased 
expression of PARP-1, Bax and Bid.  Based on these data, we tested the second 
hypothesis that p53 regulates the expression of PARP-1, which induces necrosis after 
IRI. 
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Methods 
Immunostaining: Briefly, the mouse kidney sections or cell samples were rehydrated, 
incubated in PBS containing 0.1% sodium dodecyl sulfate (SDS; Sigma) for 5 min and 
incubated with antibodies, including anti-p53 (Cell Signaling, 1 in 1000) overnight at 4°C. 
The slides then were treated with FITC -labeled secondary antibodies (Jackson Immuno 
Research). Samples were viewed using a Leica fluorescent microscope or confocal 
microscope and the images were captured using a computerized microscope recording 
system.  
Immunofluorescence detection for GFP. Cell sample sections were processed for 
immunostaining as described previously (192). Samples were viewed using a Leica 
fluorescent microscope or confocal microscope and the images were captured using a 
computerized microscope recording system. 
Cell culture and in vitro hypoxia. Primary proximal tubule epithelial cells were isolated 
from PT-specific p53 KO or WT male mice and cultured as described previously (35, 66). 
Renal proximal tubule cell lines (pig LLC-PK cell line and human HK-2 cell line) were 
cultured to 80-90% confluency in normal media, and exposed to hypoxic conditions. 
Cells were placed into GasPak plastic pouches (BBL GasPak Pouch Systems, Becton 
Dickinson), tightly sealed and placed back into the incubator for the indicated times. 
These pouches can generate a CO2-enriched hypoxic microenvironment with an oxygen 
concentration < 2% and a CO2 concentration > 4% within 2 h of incubation (modified 
from manufacturer’s instruction). 
Gene delivery. For the in vitro experiments, tubular cell lines were transfected with 
expression constructs for 1 d. For the experiments in which the cells were treated with 
GFP-p53 (Addgene, Cambridge, MA), cells were transfected with GFP-p53 plasmid for 
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24 to 48 h. The GFP-PARP-1 was obtained from Dr. Heinrich Leonhardt (Ludwig 
Maximilians University Munich). 
Western blot analysis. Briefly, cell samples (50 μg protein/lane) were separated on 
10% SDS-PAGE gels and then transferred to immobilon membranes (Millipore, Bedford, 
MA). The membranes were incubated with anti-p53 and anti-PARP-1 (Cell Signaling, 
Beverly, MA antibodies overnight at 4°C. After washing, the membranes were incubated 
with horseradish peroxidase-conjugated secondary antibodies against the appropriate 
primary antibodies (1:5,000, Vector Laboratories, Burlingame, CA), exposed to Western 
Lighting Plus-ECL (NEL104001EA; PerkinElmer, Waltham, MA), and then developed 
with X-ray film. The area of each band was analyzed using NIH image software (Image 
J). The relative densities were measured by dividing the density of target protein by the 
density of loading control (GAPDH) for the same lane. Then the fold changes were 
calculated by dividing each of the relative densities of target protein by the relative 
density of WT-sham. The variability of the relative density of control group was 
calculated by normalizing the individual values of the controls to the mean of the control 
group. 
Statistics. All data are expressed as means ± SE. An unpaired t-test was used to 
compare the means of two different groups. A P value < 0.05 was considered statistically 
significant. 
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Results  
Successful transfection of PARP-1-GFP and p53-GFP plasmids in the kidney. First, 
we analyzed the expression of PARP-1-GFP and p53-GFP with the plasmid vector, p53-
GFP, in LLC-PK1 cell line. Indeed, immunoblotting demonstrated that the expression of 
PARP-1 and p53 were induced (Fig. 21) after transfection. Their molecular weight was 
also as predicted.  
To test if p53 or PARP-1 translocate from nucleus into mitochondria, we analyzed 
the localization of PARP-1 and p53 after H2O2 or hypoxia-reoxygenation treatment. 
PARP-1- and p53-GFP did not translocate into mitochondria after hypoxia-reoxygenation 
or H2O2 treatment. As expected, the signals of PARP-1 and p53-GFP were mainly 
detected in the nucleus (Fig. 22, 23). After 4 hours of H2O2 treatment, the signals from 
PARP-1- and p53-GFP were still mainly in the nucleus without significant increase in the 
mitochondria (Fig. 22, 23). We repeated those experiments at different time points and 
with different H2O2 dosage; however, no significant mitochondrial translocation was 
observed. We concluded that mitochondrial translocation of PARP-1 or p53 was not the 
main mechanism for PARP-1- or p53-induced necrosis.  
Knockout of p53 reduces PARP-1 expression in primary tubular cells. Since we 
observed a decreased expression of PARP-1 in PTp53 knockout mice, we postulated 
that p53 induces necrosis by increasing PARP-1 expression. To test this hypothesis, we 
used primary proximal tubular cells isolated from WT and PTp53 KO mice. Indeed, with 
hypoxia-reoxygenation treatment, p53 KO primary PT cells had decreased expression of 
PARP-1 after injury. Similarly, the expression of PARP-1 was heightened after over 
expressing p53 in LLC-PK1 cells (Fig. 24). These data suggest that p53 can regulate 
PARP-1 expression after activation. 
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Figure 21: Western blot showing the successful transfection of p53 and PARP-1 
plasmids with LLC-PK1 cells. 
GFP-p53 and GFP-PARP-1 both were located above their original molecular bands, 
indicating bigger molecule weight.   
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Figure 22: Localization of GFP-p53 in transfected LLC-PK1 cells with or without H2O2 
treatment. 
Most of the GFP signals (green) were detected in nucleus (DAPI, Blue) before or after 
H2O2 treatment. No apparent mitochondrial translocation was detected.    
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Figure 23: Localization of GFP-PARP-1 in transfected LLC-PK1 cells with or without 
H2O2 treatment. 
Most of the GFP signals were detected in nucleus before or after H2O2 treatment. No 
apparent cytoplasm signal was detected.    
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Figure 24: p53 regulates PARP-1 expression. 
(A). PARP-1 expression in primary cell culture from WT and PTp53 KO mice with 
hypoxia-reoxygenation treatment. (B, C). Western blot showing the expression of PARP-
1 in LLC-PK1 after transfecting with GFP-p53 plasmid. * P < 0.05 compared with WT; n 
= 3. 
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Discussion  
Our study used p53-GFP expression system to track p53 movement within the cell 
after H2O2 and hypoxia treatment. This system allowed us to locate p53 without the 
limitation of antibody specificity. We did not observe an increased signal of p53 in the 
mitochondria at various time points and with different H2O2 treatment dosages. It 
suggests that p53-induced necrosis probably employs a mitochondria translocation-
independent mechanism. Our further analyses, along with in vivo studies, suggest that 
the regulatory effect of p53 on the expression of PARP-1 might be partially responsible 
for necrotic cell death induced by p53.  
The p53 tumor suppressor is activated and stabilized in response to cellular stress 
such as DNA damage or hypoxia (99, 166). The final outcome of p53 activation depends 
largely on the initial injury, the level of p53 activation, and the cell type, ranging from mild 
injury such as senescence to severe damage like apoptosis or necrosis (165, 167). 
Multiple activators that stimulate the activation of p53 also play a role in activating 
PARP-1 (68).  PARP-1 activation depletes NAD+ and releases AIF, which lead to 
necrotic cell death.  The initial response to DNA damage by both p53 and PARP-1 is to 
repair the damaged DNA and thus maintain genomic integrity (73, 80).  Can p53 and 
PARP-1 act independently or synergistically to carry out their functions and possibly 
regulate necrosis? 
The interaction between p53 and PARP-1 has long been recognized.  In senescent 
cells with telomere shortening (161), PARP-1 binding was shown to be critical for p53 
activation and function. p53 and PARP-1 interaction was also demonstrated in cells 
undergoing apoptosis in response to DNA damage, independent of poly(ADP-
ribosyl)ation of p53 (102). Interestingly, in DNA damaged neurons, PARP-1 regulated 
p53 transcription activity by poly(ADP-ribosyl)ation (122), which was further supported 
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by studies in irradiation-induced DNA damaged cell lines, where pharmacological or 
genetic deletion of PARP-1 modulated p53 activation (158, 175).  
While these reports established a role for PARP-1 in regulation of p53 activity, a 
reciprocal regulation of PARP-1 by p53 was described by Montero et al. in ROS-induced 
cell death (127).  Genetic deletion of p53 conferred increased resistance to ROS and 
PARP-mediated necrotic cell death (127).  PARP activity at baseline and after ROS 
stimulation was reduced in the absence of p53. These evidences suggest that the 
functions of p53 and PARP-1 are sometimes dependent on each other.  
A regulatory effect between these two molecules is supported by our study here. In 
our kidney injury model, we showed that deletion of p53 in the proximal tubule not only 
significantly reduces p53 activation, but also leads to decreased expression levels of 
PARP-1 (see chapter 1). This observation suggests that p53 might have a role in 
regulating the expression of PARP-1. In this chapter, we went further to test this possible 
mechanism for p53-induced necrosis: we showed that the expression of PARP-1 in 
primary tubular cells from PTp53 knockout kidney was decreased after hypoxia-
reoxygenation treatment compared with WT tubular cells; the expression of PARP-1 in 
LLC-PK1 after transfecting with GFP-p53 plasmid was also increased without injury. 
These data suggest that p53 regulates the expression of PARP-1, which induces 
necrosis. Our data suggest that p53 regulated-PARP-1 expression might play an 
important role in necrosis after IRI. This mechanism might be able to explain part of the 
protective effect we saw in PTp53 knockout mice. However, p53 and PARP-1 both have 
multiple functions other than inducing necrosis. A comparison of renal function, 
histopathology, necrosis and apoptosis demonstrated that p53 deletion had a superior 
protective effect compared to PARP-1 deletion. In order to determine if PARP-1 can 
independently regulate necrosis, we generated PARP-1/PTp53 double knockout mice 
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and determined the effect of double deletion of p53 and PARP-1 and these results are 
presented in the next chapter. 
In mitochondria isolated from Bax/Bak double knockout mice, oxidative stress 
triggers the p53 translocation to the mitochondria and induces the formation of a CypD-
p53 complex that promotes MPTP opening and necrosis (179).  These results were 
supported by other studies demonstrating p53-CypD interaction in MPTP-dependent 
necrosis in different cell models, including neuronal (215), pancreatic (26), and 
osteoblast cells (216).  Although these results provide a novel mechanism by which 
CypD is activated to trigger MPTP, a few questions about the universal nature of this 
interaction in MPTP remain to be answered. For example, the formation of MPTP in 
mitochondria lacking p53 and the absence of p53 involvement in calcium-induced MPTP 
opening are intriguing (95).  Our in vitro studies using H2O2 and hypoxia-reoxygenation 
injury did not show an increased translocation of p53 into mitochondria. Most of the p53 
signals were detected in the nucleus, indicating a nucleus-involved mechanism rather 
than a mitochondrial translocation-dependent mechanism for necrosis in renal epithelial 
cells. We acknowledge that GFP tagged p53 or PARP-1 have a bigger molecular weight 
and possibly affect their translocation; however, this is not very likely, because the GFP 
tag is in the C-terminal and will not alter the nuclear locating sequence, which is located 
in the N-terminal of p53. Further, non-GFP-tagged p53 or PARP-1 transfection did not 
result in increased expression of either molecule in the mitochondria as demonstrated by 
immunostaining (data not shown). 
In summary, our data suggest that there is a regulatory effect of p53 on the 
expression of PARP-1 in our injury model. p53-induced PARP-1 expression might be an 
important mechanism by which the activation of p53 after IRI triggers tubular necrosis 
and renal dysfunction. Although the mitochondrial translocation of p53 is an intriguing 
mechanism as shown in other studies, we did not observe a significant increase in p53 
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translocation in our model. Other mechanisms of p53-induced necrotic cell death, such 
as activation of Bax/Bid to induce MOMP and induction of ferroptosis, are discussed in 
chapter 1 and chapter 3 respectively. 
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CHAPTER 3: THE EFFECT OF DOUBLE KNOCKOUT OF PARP-1/PTp53 ON IRI4 
 
Introduction  
Ischemic renal injury is characterized by extensive cell death in proximal tubule S3 
segment (16, 17). Ischemia/reperfusion to the kidney parenchyma leads to many 
secondary effects including dysfunction of cellular energy metabolism, production of 
ROS, and DNA damage, which leads to activation of the nuclear repair enzyme PARP-1 
and the transcription factor p53 (180). Activation of these molecules induces necrotic 
and apoptotic tubular cell death. Better understanding the role of these two molecules in 
necrotic cell death is crucial for creating therapeutic drugs that target necrotic pathway. 
The tumor suppressor protein p53 is an anti-oncogene known for its ability to activate 
multiple target genes in response to diverse stress conditions.  Increased 
expression/activity of these p53 targets could stimulate prominent biological functions 
including cell cycle arrest, apoptosis, senescence, metabolism, and autophagy (99, 166). 
Recent studies revealed roles for p53 in regulating necrotic cell death by activating 
independent signaling pathways that include induction of MPTP, altered mitochondrial 
function and dynamics. On the other hand, p53 also regulates the expression of 
SLC7A11 and thus plays a role in ferroptosis, which is a novel type of cell death that 
depends on the over production of ROS and iron overload (37, 79, 104). SLC7A11 is a 
glutamate/cysteine carrier in the cell membrane that facilitates the transport of cysteine 
into the cell and defends against ROS production and ferroptosis.  Although recent 
                                                          
4 Some of the materials presented in this chapter were previously published: 1. Yuan 
Ying, Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted 
deletion of p53 in the proximal tubule prevents ischemic renal injury (183). 2. Yuan Ying 
and Babu J. Padanilam, Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D 
-overlapping pathways of regulated necrosis? (184) 
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studies suggest that ferroptosis might be implicated in IRI (47, 115, 118), the role of p53 
in regulating ferroptosis after ischemic injury has never been investigated. This chapter 
investigates the contribution of p53-induced ferroptosis in renal injury. 
In chapter 1, we showed that PTp53 knockout mice have lower levels of PARP-1 
after IRI, suggesting that p53 might play a role in regulating PARP-1 expression. This 
might, in part, explain why the kidney has reduced necrosis in the absence of p53. 
However, PARP-1 has other functions such as modifying other transcriptional factors 
and enzymes after its activation, while p53 also induces apoptosis, ferroptosis, and 
regulates energy production.  
Given the marked interest to pharmacologically target necrotic pathways in IRI, 
delineation of these pathways may provide key insights to our understanding of the 
pathophysiology of IRI and to develop novel therapeutic strategies. In chapters 1 and 2 
we demonstrated that p53 can regulate the expression of PARP-1 in vivo and in vitro. It 
is important to test if double knockout of PARP-1/PTp53 in the kidney further protects 
the kidney from IRI. We hypothesized that double knockout of PARP-1/PTp53 in the 
kidney will additively or synergistically protect the kidney from IRI, because both 
molecules have other functions besides inducing necrosis. 
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Methods (183) 
Generating PARP-1/PTp53 DKO mice. Homozygous p53–floxed mice (C57BL/6J 
background) and PARP-1 knockout mice (PARP-1 -/-, 129S1/svImJ background) were 
obtained from Jackson Laboratories (Bar Harbor, ME). The breeding strategy for 
transgenic mice that expressed Cre recombinase under the control of kidney-specific 
Pepck promoter (Pepck-Cre) was reported elsewhere (13). Knockout mice with the p53 
gene specifically disrupted in renal proximal tubular epithelial cells (genotype p53fl/fl, 
Cre+/-) were created by mating p53-floxed mice with pepck-Cre transgenic mice. Then 
heterozygote mice (genotype PARP-1 +/- p53fl/-, Cre+/-) were generated by breeding 
PARP-1 -/- mice and p53fl/fl, Pepck-Cre+/-. Breeding those heterozygote mice we got 
double knockout mice (PARP-1 -/- p53fl/fl, Cre+/-), single knockout mice (PARP-1 -/- or 
p53fl/fl, Cre+/-), and wild type mice with mixed background (PARP-1 +/+ p53fl/fl, Cre-). A 
routine PCR protocol was used for genotyping from tail DNA samples with the following 
primer pairs: Cre, 5’-CGGTGCTAACCAGCGTTTTC-3’ and 5’- 
TGGGCGGCATGGTGCAAGTT-3’; PARP-1, 5’-CCAGCGCAGCTCAGAGAAGCCA-3’, 
5’-CATGTTCGATGGGAAAGTCCC-3’ and 5’-AGGTGAGATGACAGGAGATC-3’; and 
p53, 5’-GGTTAAACCCAGCTTGACCA -3’ and 5’-GGAGGCAGAGACAGTTGGGAG-3’. 
All animals were born at the expected Mendelian frequency. They were of normal size 
and did not display any gross physical or behavioral abnormalities. Animal experiments 
were approved by the Institutional Animal Care and Use Committee of the University of 
Nebraska Medical Center. 
Induction of ischemic renal injury in mice.  Two 2 cm dorsal flank incisions were 
made in the skin and muscle layer on the abdominal cavity.  The kidney was exposed to 
visualize and isolate the renal pedicle. A microvascular clamp was placed on each renal 
pedicle to achieve complete cessation of arterial blood flow for 30 min to induce renal 
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ischemic injury.  The animal was placed on a heating board during this time period to 
maintain body temperature at 37 ℃.  The clamps were then removed and the abdomen 
was closed using 1-2 skin staples. Animals were sacrificed at 24 hours post-surgery.  
Blood was collected at 24 h following the injury.   
Sham operation in mice.  Mice were anesthetized with ketamine and xylazine as 
described for ischemic renal injury procedure.  A dorsal flank incision was performed as 
in IRI.  The kidneys were visualized but not touched.  The abdomen was closed with skin 
staples.  Skin sutures/staples were removed when animals were sacrificed post-surgery. 
Ferrostatin-1 administration: Mice were injected intraperitoneally with 10 mg/Kg 
ferrostatin-1 30 min before IRI. Then the same protocol was used as described in mouse 
surgery section.  
Measurement of plasma creatinine and BUN. Plasma creatinine and BUN were 
measured to evaluate renal function using a Quantichrom assay kit (BioAssay Systems, 
Hayward, CA) according to the manufacturer’s protocol. 
Morphological studies. Wild type and knockout mice that underwent IRI were 
sacrificed at 1 d. The kidneys then were processed at the University of Nebraska 
Medical Center histology core facility. Briefly, kidneys were fixed in formalin, embedded 
in paraffin, and cut into 5 μm sections. The tissue sections were then stained with PAS.  
Immunofluorescence for neutrophils. Formalin-fixed mouse kidney sections were 
processed for immunostaining as described previously (192). The slides were 
sequentially incubated with rabbit anti-mouse neutrophil antibody (Accurate, Westbury, 
NY) at a 1:100 dilution overnight at 4 ℃, followed by FITC-conjugated goat  anti-rabbit 
IgG (Vector Labs, Burlingame, CA) at a 1:200 dilution for 1 h at room temperature. 
Neutrophil infiltration was quantified by counting the number of stained cells per field. 
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Apoptosis detection by TUNEL staining. TUNEL staining of kidney tissue sections 
was carried out using the In Situ Cell Death Detection kit, Fluorescein (Roche, 
Mannheim, Germany) according to manufacturer’s protocol. 
Western blot analysis. Briefly, whole renal tissue extracts (80 μg protein/lane) were 
separated on 10% SDS-PAGE gels and then transferred to immobilon membranes 
(Millipore, Bedford, MA). The membranes were incubated with anti-p53 (Cell Signaling, 
Beverly, MA), anti-PARP-1 (Cell Signaling), anti-p21 (Santa Cruz, Santa Cruz, CA), anti-
activated Bax (Santa Cruz), anti-SLC7A11 (Abcam, Cambridge, MA), and anti-GAPDH 
(Santa Cruz) antibodies overnight at 4°C. After washing, the membranes were incubated 
with horseradish peroxidase-conjugated secondary antibodies against the appropriate 
primary antibodies (1:5,000, Vector Laboratories, Burlingame, CA), exposed to Western 
Lighting Plus-ECL (NEL104001EA; PerkinElmer, Waltham, MA), and then developed 
with X-ray film. The area of each band was analyzed using NIH image software (Image 
J). 
Statistics. All data are expressed as means ± SE. One way ANOVA was used to 
compare the mean values of all groups, followed by Tukey's multiple comparison tests to 
compare the mean values between two groups. A P value < 0.05 was considered 
statistically significant. 
 
 
 
 
 
 
 
 
101 
 
Results  
Successful deletion of PARP-1 and PT-specific p53 in the kidney. First, we used 
whole kidney samples to analyze the expression of PARP-1 and p53 before and after 
injury. The expression of PARP-1 (Fig. 25) was absent in PARP-1 single knockout mice 
and PARP-1/PTp53 DKO mice, which were consistent with our genotyping results. 
Similarly, the expression of p53 and one of its target genes, p21 (Fig. 25) was decreased 
in p53 knockout mice and PARP-1/PTp53 double knockout mice after IRI. Western blot 
analysis showed the levels of activated Bax were enhanced in the kidney of wild type 
mice compared with that of PARP-1/PTp53 DKO mice 24 h after IRI. Collectively, these 
data confirmed the successful deletion of PARP-1 and PTp53 in the kidney.  
Western blot showed decreased activation of Bax in PARP-1 KO, PTp53 KO and 
PARP-1/PTp53 DKO mice compared with that of WT mice 24 h after IRI (Fig. 25). The 
expression of p21, a transcriptional target of p53, was also reduced in PARP-1 KO, 
PTp53 KO and PARP-1/PTp53 DKO mice after IRI in contrast with WT mice. These data 
suggest that double deletion of PARP-1 and p53 in the proximal tubule decreases 
apoptotic cell death after IRI. 
Double knockout of PARP-1 and PTp53 reduced deterioration of renal function after 
IRI. To test whether double knockout of PARP-1 and PTp53 in the kidney protects 
kidneys from IRI, the levels of BUN and creatinine after IRI in KO mice and in WT mice 
were assessed. BUN levels were significantly increased in WT mice 24 h after IRI 
compared with WT sham-operated mice. The increase in BUN level was significantly 
less in PTp53, PARP-1 single KO mice, and PARP-1/PTp53 DKO mice after IRI 
compared with WT mice (Fig. 26A). Elevated plasma creatinine levels were also seen in 
WT mice 24 h after IRI compared with sham-operated mice. Similar to the BUN levels, 
the increase of plasma creatinine was less in PTp53 KO and PARP-1/PTp53 DKO but 
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not in PARP-1 single KO mice compared with WT 24 h after IRI (Fig. 26B). The most 
significant decreases in BUN and creatinine were observed in PARP-1/PTp53 DKO 
mice. These data suggest that double knockout of the PARP-1 and p53 gene in the 
kidney further protects renal functional from ischemic injury. Double knockout of PARP-
1/PTp53 has stronger effects on kidney function than single knockout mice, which 
suggests an additive protective effect. 
Double knockout of PARP-1 and PTp53 decreased renal histological damage and 
necrosis after IRI. As expected, kidneys from WT mice after 24 h IRI showed widespread 
necrosis, brush border blebbing, sloughed cells, and cast formation in the proximal 
straight tubule, whereas these features were much less apparent in kidneys from PTp53 
KO mice and PARP-1/PTp53 DKO mice. The histological changes after IRI were 
quantified by counting and scoring the percentage of tubules that displayed tubular 
necrosis, cast formation, and tubular dilation (Fig. 27). The cumulative score of 
histological damage in the outer medulla at 1 day was significantly lower in PARP-
1/PTp53 DKO kidneys compared with WT and single KO kidneys post-IRI. These data 
demonstrated that gene ablation of PARP-1/PTp53 reduced tubular damage even 
compared with single KO mice.  
Renal inflammation was reduced after IRI in PTp53 KO and PARP-1/PTp53 DKO 
mice. The infiltration of leukocytes in the outer medulla of WT and KO mice at 24 hours 
post-IRI was assessed for neutrophils using immunostaining. As shown in representative 
photographs (Fig 28), WT mice exhibited increased infiltration of neutrophils in the outer 
medulla, which was attenuated in PTp53 KO and PARP-1/PTp53 DKO mice. The 
numbers of positively stained cells were counted in a blinded manner and quantitative 
data indicated that the accumulation of neutrophils was reduced in the outer medulla of 
PTp53 KO mice, and PARP-1/PTp53 DKO mice, compared to that of WT and PARP-1 
KO mice after IRI (Fig. 28). 
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Double knockout of PARP-1 and PTp53 decreased apoptosis after IRI. To determine 
whether there is a change of apoptotic levels in the outer medulla of WT mice compared 
with KO mice, TUNEL assay was performed to assess apoptotic tubular cells. The outer 
medulla of wild type mice exhibited increased numbers of TUNEL-positive cells 
compared with that of PTp53 KO and PARP-1/PTp53 DKO mice but not PARP-1 KO 
mice (Fig. 29). These data suggest that double deletion of PARP-1/PTp53 or PTp53 
alone in the kidney decreases apoptotic cell death after IRI, while PARP-1 KO mice do 
not have these protective effects.  
Loss of p53 increased SLC7A11 after IRI. To investigate whether knockout of p53 
regulates ferroptosis in the kidney knockout mice, SLC7A11, a glutamate/cysteine 
carrier, was measured using western blot (Fig. 30). The expression of SLC7A11 is 
inhibited by p53 as shown in other studies. As described earlier, the expression of p53 
(Fig. 25) was decreased in PARP-1, PTp53 knockout mice and PARP-1/PTp53 double 
knockout mice after IRI. On the opposite, the expression of SLC7A11 was significantly 
higher in single knockout and PARP-1/PTp53 double knockout mice. These data 
suggest that increased SLC7A11 channel in the cell might inhibit ferroptosis by 
increasing intracellular cysteine and glutathione synthesis.  
Ferrostatin-1 protected kidney function in PARP-1 KO mice. Previously other groups 
reported the involvement of ferroptosis in IRI. We next asked if inhibition of ferroptosis 
could further protect PARP-1 KO mice from IRI. Indeed, our data showed that 
administration of ferrostatin-1 30 minutes before surgery significantly decreased plasma 
levels of BUN and creatinine compared with PARP-1 KO mice treated with vehicle (Fig. 
31). It indicates that ferroptosis inhibited by ferrostatin-1 is probably mediated by p53. 
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Figure 25: The expression of p53, PARP-1, p21, and Bax after IRI. 
Western blot showing the expression levels of p53, PARP-1, p21 and Bax in WT, PTp53 
KO, PARP-1 KO, and PARP-1/PTp53 DKO mice 1 d after IRI. GAPDH level was used 
as a loading control.  
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Figure 26: Kidney function after IRI in single knockout and double knockout mice. 
(A) Plasma BUN and (B) Creatinine levels from WT, PTp53 KO, PARP-1 KO, and 
PARP-1/PTp53 DKO mice (n = 4) at 1d after IRI. * P < 0.05 compared with WT-IRI; # P 
< 0.05 compared with both PTp53 KO and PARP-1 KO-IRI; & P < 0.05 compared with 
PARP-1 KO-IRI;  † P < 0.05 compared with Sham by Tukey's multiple comparison test. 
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Figure 27: Kidney histological damage in single and double knockout mice after IRI. 
(A). Histological damage in the outer medulla assessed in PAS-stained kidney sections 
was scored by counting the percentage of tubules that displayed tubular necrosis, cast 
formation, and tubular dilation as follows: 0 = normal; 1 = < 10%; 2 = 10–25%; 3 = 26–
50%; 4 = 51–75%; and 5 = > 75%. Ten fields (200× magnification) per kidney were used 
for counting. (B). The number of necrotic tubules in the outer medulla per field was 
counted in WT, PTp53 KO, PARP-1 KO, and PARP-1/PTp53 DKO mice. * P < 0.05 
compared with WT-IRI and PARP-1 KO-IRI; # P < 0.05 compared with WT-IRI, PTp53 
KO-IRI and PARP-1 KO-IRI; † P < 0.05 compared with Sham by Tukey's multiple 
comparison test, n = 6. 
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Figure 28: Typical neutrophil accumulation in the outer medulla of WT, PARP-1 KO, 
PTp53 KO, and PARP-1/PTp53 DKO mice at 1 d post IRI. 
Number of neutrophils was measured in 10 randomly chosen high magnification (200×) 
fields per kidney. * P < 0.05 compared with WT-IRI and PARP-1 KO-IRI; † P < 0.05 
compared with Sham by Tukey's multiple comparison test; n = 4.   
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Figure 29: TUNEL staining for apoptotic cells in single and double knockout mice. 
Apoptotic cells were assessed by In Situ Cell death detection assay in WT, PARP-1 KO, 
PTp53 KO, and PARP-1/PTp53 DKO mice at 1 d after IRI.  Number of TUNEL positive 
cells was measured in 10 randomly chosen high magnification (200×) fields per kidney. * 
P < 0.05 compared with WT-IRI and PARP-1 KO-IRI; † P < 0.05 compared with Sham 
by Tukey's multiple comparison test; n = 5.   
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Figure 30: The expression of p53 and SLC7A11 after IRI in PARP-1 and p53 knockout 
mice.  
Western blot showing the expression levels of p53, and SLC7A11 in WT, PTp53 KO, 
PARP-1 KO, and PARP-1/PTp53 DKO mice 1 d after IRI. GAPDH level was used as a 
loading control.  
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Figure 31: Kidney function after IRI in PARP-1 KO mice with or without ferrostatin-1. 
(A) Plasma creatinine and (B) BUN levels from PARP-1 KO mice with or without of 
ferroptosis inhibitor ferrostatin-1 treatment (n = 3-4) at 1d after IRI. * P < 0.05 compared 
with PARP-1 KO-IRI; † P < 0.05 compared with Sham.  
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Discussion  
Ischemic renal injury is strongly associated with proximal tubular cell necrosis and 
apoptosis (71). It has been shown that interference with many cell death mediators 
provides protective effects on renal function (76, 87, 88). Proximal tubular cell necrosis 
directly contributes to the decline in GFR and leads to a sequence of pathophysiological 
changes in the kidney. During the last few years, certain types of necrotic cell death 
have been well recognized. Among these pathways, p53 has gained particular attention 
because of its key role in senescence, apoptosis and even necrosis (166). Indeed, our 
studies in chapter 1 showed that PTp53 KO significantly improves kidney function and 
reduces apoptosis after IRI, along with attenuated inflammatory response and later 
fibrosis. These findings support the concept that p53 is a critical mediator of 
apoptosis/necrosis after IRI. In this chapter, we showed that double knockout of PARP-1 
and PT-specific p53 in the kidney significantly attenuated the decline in kidney function 
after IRI compared with wild type and single knockout mice. Although PARP-1 single 
knockout mice had slightly better plasma BUN levels compared with WT, their kidney 
morphology was not well preserved as PARP-1/PTp53 double knockout mice and p53 
single knockout mice. This suggests that PARP-1- or p53-mediated other mechanisms 
are also involved in the pathogenesis of IRI. Interestingly, animals with both PARP-
1/PTp53 genes deleted had less apoptotic cell death and even lower inflammatory 
infiltration in the kidney. Similar effects were seen in p53 single knockout mice. There 
data suggest that PARP-1 and p53 have both overlapping and distinctive roles in the 
pathogenesis of IRI. 
Upon DNA damage, p53 is activated and stabilized by reduced activity of MDM2 (99, 
166). Various signaling pathways including senescence, cell cycle arrest, apoptosis, 
autophagy, and necrosis can be activated upon p53 activation (165, 167). Those signals 
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that activate p53 also can induce the activation of PARP-1.  The interaction between p53 
and PARP-1 was reported previously by many groups. Our data in chapter 2 also 
established a regulatory impact of p53 on the expression of PARP-1; however, is the 
protective effect we have seen in PTp53 KO mice only because the expression of 
PARP-1 decreases in those mice? 
To answer this question, we generated PARP-1/PTp53 DKO mice with mixed 
background. We have shown that PTp53 KO and PARP-1/PTp53 DKO mice had better 
kidney function and renal histological scores compared with PARP-1 KO mice. It 
suggests that p53 have its unique function in mediating IRI injury. PTp53 KO and PARP-
1/PTp53 DKO mice had less apoptosis and inflammatory reaction after IRI, suggesting 
the unique roles of p53 in those pathophysiological processes, which were not apparent 
in PARP-1 KO mice. PARP-1/PTp53 DKO mice had lowest level of BUN and histological 
damages compared with PTp53 single knockout mice, indicating deletion of PARP-1 in 
the kidney added more protection against IRI to PTp53 KO kidney. These data suggest 
that although p53 regulates the expression of PARP-1, they both have their unique 
function in the pathogenesis of IRI. 
Interestingly, our data also suggested the involvement of a novel type of cell death in 
IRI: ferroptosis.  Ferroptosis is a type of iron-dependent cell death characterized by 
accumulation of lipid peroxides (37, 104). Morphologically, ferroptosis is characterized 
by the presence of small mitochondria with condensed membrane densities, and is not 
associated with chromatin condensation, plasma membrane rupture, swelling of 
cytoplasmic organelles, or the formation of cytoplasmic vesicles/vacuoles (37). Usually 
blocking other types of cell death has not direct effect on the process of ferroptosis. Lipid 
peroxidation and ferroptosis are inhibited physiologically by antioxidant mechanisms 
including glutathione peroxidase 4 (Gpx4), the only enzyme that reverses the oxidation 
of membrane lipids. The function of Gpx4 depends on the glutamate/cysteine antiporter 
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in the plasma membrane known as system Xc-.  SLC7A11 (xCT), together with SLC3A2, 
encodes the heterodimeric amino acid transport system Xc-, which mediates cysteine-
glutamate exchange (47, 147, 176). Decreased cysteine transport results in reduced 
intracellular glutathione (reduced form) levels and increased production of ROS (48, 
182). The activation of p53 suppresses transcription of SLC7A11, leading to reduced 
cysteine uptake, intracellular glutathione (GSH) and consequent increased ROS levels 
(79).  Thus, in p53 activated cells, the sensitivity to ferroptosis is increased.   
We observed a decreased expression of SLC7A11 in wild type mice, but an 
enhanced expression in PARP-1/PTp53 DKO mice, which have lower levels of p53. Our 
data suggest that by decreasing the expression of SLC7A11, activated p53 plays a role 
in mediating ferroptosis. Indeed, when ferroptosis inhibitor ferrostatin-1 was 
administered to PARP-1 single knockout mice, we observed a better kidney function in 
those mice. This suggests that ferroptosis after IRI possibly arises through a p53-
mediated mechanism. Interestingly, PARP-1/PTp53 DKO mice have the highest level of 
SLC7A11 expression than both single knockout mice, suggesting that the involvement of 
PARP-1 in controlling SLC7A11 expression, which has not been reported in any 
previous studies. The exact mechanism by which SLC7A11 expression is exacerbated in 
PARP-1/PTp53 DKO mice remains to be defined.  Nevertheless, deletion of both PARP-
1 and p53 may drastically reduce ferroptosis by the induction of SLC7A11 and may 
explain why double knockout mice have better kidney function and less necrosis-like cell 
death compared to the respective single KO mice. 
In summary, our data further supported that although p53 regulates PARP-1 
expression in the PT, which might play an important role in necrosis after IRI, it can only 
explain part of the protective effect we saw in PTp53 knockout mice. p53 and PARP-1 
both have multiple unique functions other than inducing necrosis. p53-induced 
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ferroptosis is implicated in the pathogenesis of IRI, and is likely through a PARP-1 
independent mechanism.  
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CHAPTER 4: THE EFFECT OF DOUBLE KNOCKOUT OF PARP-1 /CYPD ON IRI5 
 
Introduction  
Necrotic cell death, particularly in proximal tubule S3 segment in the outer medulla, 
is one of the key features of the IRI pathogenesis (16, 17, 162). Tubular cell necrosis 
after IRI directly contributes to the decline in kidney function and triggers the progression 
to fibrosis in the kidney (16). A series of necrotic cell death inducers have been involved 
in this process. Our lab previously reported that two important types of necrotic cell 
death involved in AKI: PARP-1- and CypD-induced cell death (34, 35, 192). Single 
knockout of PARP-1 or CypD mice showed reduced necrotic tubules and better 
outcomes of kidney function. However, whether these two molecules induce necrosis 
independently or synergistically after IRI is not defined. In order to determine their 
relative contribution, we present a study using double knockout of PARP-1- and CypD to 
reveal if there are any intertwines and/or crosstalk between these two molecules in 
inducing necrosis after IRI. 
Activation of PARP-1 is required for DNA repair and in the presence of DNA single- 
or double-strand breaks (68), PARP-1 transfers the ADP-ribose moiety of NAD+ to 
various nuclear proteins. Excessive activation of PARP-1, such as in the setting of IRI, 
can lead to glycolytic inhibition (35), depletion of NAD+, and consequent depletion of 
ATP in the proximal tubule (36). Because of the severe hypoxia in the outer medulla, the 
limited glycolytic capacity in the proximal tubule cells is further inhibited upon PARP-1 
                                                          
5 Some of the materials presented in this chapter were previously published: 1. Yuan 
Ying, Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted 
deletion of p53 in the proximal tubule prevents ischemic renal injury (183). 2. Yuan Ying 
and Babu J. Padanilam, Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D 
-overlapping pathways of regulated necrosis? (184) 
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activation, which makes S3 segment susceptible to necrotic cell death. Indeed, previous 
reports from our lab and others have demonstrated that PARP-1 inhibition or gene 
deletion is protective against ischemia-reperfusion (35, 124, 192), diabetes (143), 
ureteral obstruction (92), and cisplatin nephrotoxicity (91). 
A member of the polypeptidyl-prolyl cis-trans isomerase family, CypD is located in 
the mitochondrial matrix and can interact with mitochondrial inner membrane proteins to 
induce the opening of the MPTP, which is a crucial step in CypD-induced necrosis (129, 
140). As mentioned earlier, excessive activation of PARP-1, like in the setting of IRI, can 
lead to depletion of NAD+ and consequent ATP depletion. After ATP depletion, a 
sustained rise in cytosolic free Ca2+ was observed (55). It is possible that uptake of 
excessive Ca2+ by mitochondria as well as increased ROS levels in mitochondria during 
reperfusion triggers the opening of the MPTP, which needs the participation of CypD. 
This hypothesis connects these two pathways in a reasonable uniform model that has 
not been investigated before. 
Recent studies have greatly expanded our understanding about these two types of 
cell death. Our laboratory has previously established key roles for both PARP-1 and 
CypD in necrosis after IRI (34, 192); however, whether these molecules induce necrosis 
independently of each other or if their signaling pathways integrate to induce necrosis is 
unclear. Their relative contribution to the pathogenesis of IRI is also poorly understood. 
In this chapter, we hypothesized that genetic deletion of both PARP-1 and CypD 
additively protects mice from ischemic renal injury. We showed that double knockout of 
PARP-1 and CypD in the kidney significantly attenuated kidney dysfunction after IRI and 
necrotic cell death compared WT and single knockout mice. 
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Methods (183)  
Generating PARP-1/CypD DKO mice. PARP-1 knockout mice (PARP-1 -/-, 
129S1/svImJ background) and CypD knockout mice (CypD -/-, B6129 SF2/J background) 
were obtained from Jackson Laboratories (Bar Harbor, ME). The breeding strategy for 
double knockout mice is that first we bred those two single knockout mice to generate 
heterozygotes PARP-1 +/- CypD +/- mice. Then, by breeding those heterozygotes, we 
generated double knockout mice (PARP-1 -/- CypD -/-), wild type mice (PARP-1 +/+ 
CypD +/+), and single knockout mice with mixed background. A routine PCR protocol 
was used for genotyping from tail DNA samples with the following primer pairs: PARP-1, 
5’-CCAGCGCAGCTCAGAGAAGCCA-3’, 5’-CATGTTCGATGGGAAAGTCCC-3’ and 5’-
AGGTGAGATGACAGGAGATC-3’; and CypD, 5’-AAACTTCTCAGTCAGCTGTTGCCT 
CTG -3’, 5’- TTCTCACCAGTGCATAGGGCTCTG-3’, and 5’- GCTTTGTTATCCCAGCT 
GGCGC-3’. All animals were born at the expected Mendelian frequency. They were of 
normal size and did not display any gross physical or behavioral abnormalities. Animal 
experiments were approved by the Institutional Animal Care and Use Committee of the 
University of Nebraska Medical Center. 
Inducing IRI in mice. IRI was induced in mice as described previously (34, 192). All 
animals were given free access to food and water. The mice were anesthetized by 
intraperitoneal administration of a cocktail containing ketamine (200 mg) and xylazine 
(16 mg) per kilogram of body weight. Ischemic injury was induced by bilateral renal 
pedicle clamping using microaneurysm clamps (Roboz Surgical Instrument, 
Gaithersburg, MD). After 30 min of occlusion, the clamps were removed, and kidney 
reperfusion was verified visually. Sham-operated control animals underwent the same 
surgical procedure, except for the occlusion of the renal arteries. During the surgery, all 
animals were placed on a heating pad to maintain body temperature at 37 ℃. Blood 
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samples were collected from the orbital sinus under isoflurane anesthesia at 0, 6, 24 and 
48 h post-IRI for measurement of serum creatinine and blood urea nitrogen (BUN). At 
the end of each time point (1 d or 16 d), renal tissue was collected, frozen with liquid 
nitrogen, and stored at -80°C for future experiments. 
Measurement of plasma creatinine and BUN. Plasma creatinine and BUN were 
measured to evaluate renal function using a Quantichrom assay kit (BioAssay Systems, 
Hayward, CA) according to the manufacturer’s protocol. 
Morphological studies. Wild type and knockout mice that underwent IRI were 
sacrificed at 1 or 16 d. The kidneys then were processed at the University of Nebraska 
Medical Center histology core facility. Briefly, kidneys were fixed in formalin, embedded 
in paraffin, and cut into 5 μm sections. The tissue sections were then stained with PAS.  
Immunofluorescence for neutrophils. Formalin-fixed mouse kidney sections were 
processed for immunostaining as described previously (192). The slides were 
sequentially incubated with rabbit anti-mouse neutrophil antibody (Accurate, Westbury, 
NY) at a 1:100 dilution overnight at 4 ℃, followed by FITC-conjugated goat anti-rabbit 
IgG (Vector Labs, Burlingame, CA) at a 1:200 dilution for 1 h at room temperature. 
Neutrophil infiltration was quantified by counting the number of stained cells per field. 
Apoptosis detection by TUNEL staining. TUNEL staining of kidney tissue sections 
was carried out using the In Situ Cell Death Detection kit, Fluorescein (Roche, 
Mannheim, Germany) according to manufacturer’s protocol. 
Western blot analysis. Briefly, whole renal tissue extracts (80 μg protein/lane) were 
separated on 10% SDS-PAGE gels and then transferred to immobilon membranes 
(Millipore, Bedford, MA). The membranes were incubated with anti-PARP-1 (Cell 
Signaling, Beverly, MA), and anti-CypD (Santa Cruz, Santa Cruz, CA) antibodies 
overnight at 4°C. After washing, the membranes were incubated with horseradish 
peroxidase-conjugated secondary antibodies against the appropriate primary antibodies 
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(1:5,000, Vector Laboratories, Burlingame, CA), exposed to Western Lighting Plus-ECL 
(NEL104001EA; PerkinElmer, Waltham, MA), and then developed with X-ray film. The 
area of each band was analyzed using NIH image software (Image J). 
Statistics. All data are expressed as means ± SE. One way ANOVA was used to 
compare the mean values of all groups, followed by Tukey's Multiple Comparison Test to 
compare the mean values between two groups. A P value < 0.05 was considered 
statistically significant. 
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Results  
Successful deletion of PARP-1 and CypD in the kidney. First, we analyzed the 
expression of PARP-1 and CypD before and after injury in whole kidney samples. 
Indeed, the expression of PARP-1 (Fig. 32) was absent in PARP-1 single knockout mice 
and PARP-1/CypD double knockout mice. Moreover, the expression of CypD (Fig. 32) 
was absent in CypD single knockout mice and PARP-1/CypD double knockout mice. 
Together with genetyping data, it further confirmed successful deletion of PARP-1 and 
CypD in the kidney.  
Double knockout of PARP-1 and CypD reduced deterioration of renal function after 
IRI. To test whether the absence of PARP-1 and CypD protects kidney function after IRI, 
the levels of BUN and creatinine after IRI in KO mice and in WT littermates were 
assessed. BUN levels were significantly increased in WT mice 24 h after IRI compared 
with WT sham-operated mice. The increase in BUN level was significantly less in PARP-
1/CypD DKO mice after IRI compared with WT mice and CypD single knockout mice 
(Fig. 33). Plasma creatinine levels were also increased in WT mice 24 h after IRI 
compared with sham-operated mice. Similar to the BUN levels, the increase of plasma 
creatinine was less in PARP-1/CypD DKO compared with WT 24 h after IRI (Fig. 33). No 
significant difference in renal function occurred among sham-operated WT and KO mice. 
Although not statistically significant, the levels of BUN or plasma creatinine in PARP-1 or 
CypD single knockout mice were trending down compared with WT mice after IRI. These 
data suggest that double knockout of the PARP-1 and CypD gene in the kidney further 
protects renal function from ischemic injury.  
Double knockout of PARP-1 and CypD decreased renal histological damage and 
necrosis after IRI. As expected, widespread necrosis, brush border blebbing, sloughed 
cells, and cast formation were observed in the proximal straight tubule of kidneys from 
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WT mice after 24 h IRI, whereas these features were much less apparent in kidneys 
from PARP-1/CypD DKO mice. The histological changes after IRI were quantified by 
counting and scoring the percentage of tubules that displayed tubular necrosis, cast 
formation, and tubular dilation (Fig. 34). The cumulative score of histological damage in 
the outer medulla at 1 day was significantly lower in PARP-1/CypD DKO kidneys 
compared with WT kidneys post-IRI. Although the histological damage score of PARP-1 
and CypD single knockout mice was not significantly lower than WT, the number of 
necrotic tubules was significantly reduced compared with WT after IRI, while PARP-
1/CypD DKO mice had the lowest level of necrotic tubules. These data demonstrated 
that gene ablation of PARP-1/CypD reduced tubular damage and cellular necrosis.  
Renal inflammation was reduced after IRI in single KO and PARP-1/CypD DKO 
mice. The infiltration of leukocytes in the outer medulla of WT and KO mice at 24 hours 
post-IRI was assessed by immunostaining. As shown in representative photographs (Fig 
35), WT mice exhibited increased infiltration of neutrophils in the outer medulla, which 
was attenuated in PARP-1 and/or CypD KO mice. The numbers of positively stained 
cells were counted in a blinded manner and quantitative data indicate that the 
accumulation of neutrophils was reduced in the outer medulla of PARP-1 and/or CypD 
KO mice, while PARP-1/CypD DKO mice has the lowest level of neutrophil infiltration 
compared to that of WT and single KO mice after IRI (Fig. 35). 
Double knockout of PARP-1 and CypD decreased apoptosis after IRI. To determine 
whether there is a change of apoptotic levels in the outer medulla of WT mice compared 
with KO mice, TUNEL assay was performed to assess apoptotic tubular cells. The outer 
medulla of wild type mice exhibited increased numbers of TUNEL-positive cells 
compared with that of PARP-1/CypD DKO mice but not PARP-1 KO or CypD KO mice 
(Fig. 36). These data suggest that double deletion of PARP-1/CypD in the kidney 
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decreases apoptotic cell death after IRI, while PARP-1 KO or CypD KO mice do not 
have these effects. 
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Figure 32: The expression of PARP-1 and CypD before and after IRI.  
Western blots showing the expression levels of PARP-1 and CypD in WT, PARP-1 KO, 
and PARP-1/CypD DKO mice after IRI.   
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Figure 33: Kidney function in PARP-1 and CypD single and double knockout mice after 
IRI.  
(A) Plasma creatinine and (B) BUN levels from WT, PARP-1 KO, CypD KO, and PARP-
1/CypD DKO mice (n = 4-6) at 1d after IRI. * P < 0.05 compared with WT-IRI; # P < 0.05 
compared with CypD KO-IRI; † P < 0.05 compared with Sham (same genotype) by 
Tukey's multiple comparison test.   
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Figure 34: Kidney histological damage in PARP-1 and CypD single and double knockout 
mice after IRI. 
(A). Histological damage in the outer medulla assessed in PAS-stained kidney sections 
was scored by counting the percentage of tubules that displayed tubular necrosis, cast 
formation, and tubular dilation as follows: 0 = normal; 1 = < 10%; 2 = 10–25%; 3 = 26–
50%; 4 = 51–75%; and 5 = > 75%. Ten fields (200× magnification) per kidney were used 
for counting. (B).The number of necrotic tubules in the outer medulla per field was 
counted.  * P < 0.05 compared with WT-IRI; # P < 0.05 compared with WT-IRI, PARP-1 
KO-IRI and CypD KO-IRI; † P < 0.05 compared with Sham by Tukey's multiple 
comparison test; n = 6.   
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Figure 35: Neutrophil infiltration in the kidney after IRI. 
Typical neutrophil accumulation in the outer medulla of WT PARP-1 KO, CypD KO, and 
PARP-1/CypD DKO mice at 1 day post IRI. Number of neutrophils was measured in 10 
randomly chosen high magnification (200×) fields per kidney. * P < 0.05 compared with 
WT-IRI; # P < 0.05 compared with both PARP-1 KO-IRI and CypD KO-IRI; † P < 0.05 
compared with Sham by Tukey's multiple comparison test; n = 4.   
137 
 
 
  
138 
 
 
 
 
 
 
 
 
Figure 36: TUNEL staining for apoptotic cells in PARP-1 and CypD single and double 
knockout mice after IRI. 
 Apoptotic cells were assessed by In Situ Cell death detection assay in WT, PARP-1 KO, 
CypD KO, and PARP-1/CypD DKO mice at 1 day after IRI.  Number of TUNEL positive 
cells was measured in 10 randomly chosen high magnification (200×) fields per kidney. * 
P < 0.05 compared with WT-IRI, PARP-1 KO-IRI and CypD KO-IRI; † P < 0.05 
compared with Sham by Tukey's multiple comparison test; n = 4.   
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Discussion  
In this study, we showed that double knockout of PARP-1 and CypD in the kidney 
significantly attenuated the declination of kidney function after IRI compared with 
wildtype and corresponding single knockout mice. Although PARP-1 and CypD single 
knockout mice had reduced necrotic tubules in the outer medulla, their kidney function 
was not well preserved as double knockout mice. It suggests that PARP-1- or CypD-
induced necrosis is also involved in the pathogenesis of IRI and they are likely 
independent pathways. Interestingly, animals with both genes deleted had less apoptotic 
cell death and even lower inflammatory infiltration in the kidney, which supports the 
notion that double knockout of PARP-1 and CypD additively protects kidney from IRI. 
PARP-1, the most studied member, is an important nuclear enzyme that regulates 
protein functions by poly(ADP-ribosyl)ation and gene expression as a transcription 
cofactor (72). Excessive activation of PARP-1, such as in the setting of IRI, can inhibit 
glycolytic activity in the proximal tubule (35). PARP-1-induced cell death is mediated by 
its ability to deplete intracellular NAD+ and interfere with energy production. In addition, 
PARP-1 as a transcriptional regulator exerts its influence on the expression of 
inflammatory genes including NFκB (36, 69, 91), cytokines (25, 112)(57, 59)(61, 112), 
ICAM-1 (61, 187), and TLR4 (187). This explains that PARP-1 knockout mice still have 
robust inflammatory reaction even when the necrotic cell death is reduced. Inflammatory 
reaction with increased production of cytokines can further cause ROS production and 
increased secondary apoptotic cell death in PARP-1 knockout mice. The different 
consequences of PARP-1 activation in tubular cells and interstitial cells might be the key 
to understand their function as a whole in the kidney. Tissue specific knockout of PARP-
1 (for example: in the proximal tubule) will help us to better understand the role of PARP-
1 in tubular necrosis and inflammation after IRI.  
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Previous reports showed that CypD is located in the mitochondrial matrix and can 
interact with mitochondrial inner membrane proteins to induce the opening of the MPTP. 
Although numerous molecular constituents of the MPTP have been suggested to be 
required for pore formation, only CypD has been proved by gene ablation studies (8, 9, 
93). ANT in the IMM and VDAC in the OMM were considered as the candidates for the 
MPTP. However, genetic deletion studies showed that the ANT and voltage-dependent 
anion channels are dispensable for pore formation (9, 93).  
As mentioned previously, excessive activation of PARP-1, like in the setting of IRI, 
can lead to depletion of NAD+ and consequent ATP depletion (35). After ATP depletion, 
a sustained rise in cytosolic free Ca2+ occurs. Uptake of Ca2+ by mitochondria as well as 
increased ROS levels in mitochondria during reperfusion triggers the opening of the 
MPTP, which requires a functional CypD. In our model, however, the number of necrotic 
tubules is significantly lower in PARP-1/CypD double knockout mice rather than single 
knockout mice, indicating that PARP-1 and CypD probably employ different pathways 
that do not necessarily converge into the opening of MPTP. Further in vitro experiments 
are needed to clarify these hypotheses and tease out other players of necrotic cell death 
in IRI. 
In summary, double knockout of PARP-1 and CypD in the mice provides stronger 
protective effects against IRI than WT mice. Double knockout mice also have less 
inflammatory infiltration and apoptotic cell death compared with single knockout mice. 
Thus, double knockout of PARP-1 and CypD in the kidney additively or synergistically 
protects the kidney from IRI. Although the connections between these pathways were 
not revealed by our study, our data suggest that these two types of necrotic cell death 
are possible through two independent pathways. 
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DISCUSSION6  
 
Acute kidney injury 
AKI is a clinical syndrome with a rapid decline in GFR over a period of hours to days, 
leading to retention of metabolic waste and disruption of fluid, electrolytes and acid-base 
balance (16, 17). A leading cause of AKI is IRI, which results from compromised 
perfusion to renal tissue.  AKI has multiple contributing factors including low blood 
pressure, cisplatin nephrotoxicity, radiocontrast agent-induced injury, sepsis and various 
antibiotics used in the clinics. Given the numerous causes of AKI, it occurs in 
approximately 30% of all patients admitted into intensive care units and is associated 
with very high mortality rates (50-80%) (110, 141, 151). It also develops in approximately 
one-third of patients who undergo cardiac surgery (94, 137, 186). Further, for patients 
who undergo kidney transplants, post-transplant acute tubular necrosis, another cause 
of AKI, often results in delayed graft functioning and is one of the strongest predictors for 
the recurrence of end-stage kidney disease (135). Even when patients regain normal, or 
near normal, kidney function after acute episodes, they still carry significant risks for 
long-term loss of renal function and development of chronic kidney disease (119).  
Currently, no effective treatment targeting the pathogenesis of this syndrome is available 
for AKI patients. Thus, given the increasing frequency of AKI, its related morbidity and 
mortality and the increasing financial burden, effective treatment options are critically 
needed.  
                                                          
6 Some of the materials presented in this chapter were previously published: 1. Yuan 
Ying, Jinu Kim, Sherry N. Westphal, Kelly E. Long, and Babu J. Padanilam. Targeted 
deletion of p53 in the proximal tubule prevents ischemic renal injury (183). 2. Yuan Ying 
and Babu J. Padanilam, Regulation of necrotic cell death: p53, PARP1 and Cyclophilin D 
-overlapping pathways of regulated necrosis? (184) 
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There are three types of AKI: prerenal, intrarenal, and postrenal AKI. Intrarenal AKI 
or commonly ATN with the involvement of the renal parenchymal is usually irreversible 
even with sufficient perfusion (195). It represents a severe form of AKI with selected 
tubular damage. Although all segments of the nephron may be injured under a severe 
ischemic insult, the proximal tubules, particularly the S3 segment of the proximal tubule 
in the outer stripe of outer medulla is usually the most commonly involved segment 
because of limited glycolytic capacity, high energy requirement, and persistent hypoxia 
in this area (162). Necrotic cell death in the S3 segment of proximal tubule directly 
contributes to the declination of GFR. Tubular damage/cell death increases tubular fluid 
back leak through loose connections between damaged epithelial cells. Absorption 
dysfunction of the proximal tubule increases tubular fluid solutes in the downstream 
segment of the nephron, which activates tubuloglomerular feedback as more solute is 
delivered to the macula densa (16). Necrotic tubules can interact with tubular lumen 
proteins to form casts in the downstream segments and obstruct the tubular flow and 
increase back pressure in the glomerulus. All of these factors inevitably lead to a 
reduced GFR. 
Animal models use ischemic reperfusion injury usually result in this type of injury. 
Some of the pathophysiological processes in ischemic renal injury have also been 
proved to be true in other types of AKI, although every type of AKI has its unique 
characteristics. Necrotic and apoptotic cell death are implicated in multiple AKI models 
(115) and significantly contribute to its pathogenesis.  Better understanding of the 
mechanisms by which different modes of cell death occurs is critical for developing 
specific therapies targeting specific cell death pathways. The study presented here 
identified some key players in necrotic cell death such as p53, PARP-1 and CypD and 
their contribution to the pathogenesis of IRI. Our results suggest that targeting those 
144 
 
molecules in the early stage of IRI might provide therapeutic benefit, improve kidney 
function, and even reduce long term fibrosis. 
The role of p53 in ischemic renal injury  
The pathophysiologic abnormalities of IRI are characterized by changes in renal 
hemodynamics, tubular injury and cell death, and tissue inflammation (16, 106). 
Ischemia/reperfusion to the kidney parenchyma leads to direct damage to epithelial cells 
including disruption of cellular energy metabolism, production of ROS, and DNA damage, 
which cause the activation of nuclear repair enzyme PARP-1 and transcription factor p53. 
Further, activation of these molecules can initiate pathways that induce necrosis through 
opening of the MPTP, apoptotic tubular cell death through MOMP, and inflammatory 
signaling (43, 91).  For this reason, the role of p53 and PARP-1 in IRI and other kidney 
injury models has been heavily investigated.  
Several studies have previously investigated the role of p53 in IRI. Kelly et al. (88) 
first showed that p53 expression is increased in the renal medulla after IRI, and 
pharmacological inhibition of p53 using pifithrin-α can reduce renal injury in rats. 
Molitoris et al. showed that systemic administration of p53-targeted siRNA in mice 
attenuates ischemic and cisplatin-induced AKI (126).  In a recent report, Yang et al. 
administered pifithrin-α in a single dose 3 and 14 days after unilateral IRI in mice and 
showed that it relieved epithelial cell cycle arrest and inhibited fibrogenesis (180).  
However, two recent reports showed that p53 inhibition is detrimental to renal function in 
IRI.  Dagher et al. administered Pifithrin-α daily, starting at the time of bilateral IRI in rats 
and continuing for 7 days, which ultimately increased renal fibrosis (32). To add to the 
puzzle, Sutton et al. showed that global p53 deficiency or pharmacological inhibition of 
p53 exacerbates the injury by increasing and prolonging leukocyte infiltration into the 
renal parenchyma (152). These differing results suggest that the role of p53 in the 
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pathophysiology of IRI is much more complicated and still incompletely understood 
(183). 
For this reason, in chapter 1 we hypothesized that specific knockout of p53 in the 
proximal tubule reduces kidney injury and necrotic cell death in the S3 segment. We 
used knockout mice with p53 gene specifically deleted in the PT. This strategy not only 
specifically targets the proximal tubule, the major injury site of IRI (162), but also avoids 
the inhibition of normal function of p53 in other cells within the kidney. The activation of 
p53 may be crucial for the normal response of inflammatory cells recruited after IRI, in 
which the absence of p53 may prolong inflammatory responses and increase renal injury 
(152). Our data demonstrate that specific deletion of p53 gene in the proximal tubule 
significantly improves kidney function, preserves renal histology and reduces necrosis 
and apoptosis after IRI, along with attenuated inflammatory response and late-term 
fibrosis. In addition, our data from global knockout rats did not show significant 
difference in the kidney function and renal histological damage. Although we cannot 
exclude the possibility that species and model difference are accountable for the distinct 
response, these data probably indicate opposite effects of p53 activation in different cell 
types on the pathogenesis of IRI. In summary, these findings support the concept that 
p53 in the PT is a critical mediator of IRI and its inhibition or its downstream signaling 
pathways prevents IRI and are suitable therapeutic targets (183). Below we 
comprehensively discussed all the major p53-mediated mechanisms that are suggested 
by the data from this study and previous studies. 
The mechanism of p53-mediated apoptosis 
The role for p53 in apoptosis is well established.  p53 can upregulate the expression 
of several proapoptotic genes including Bax, Fas/Apo-1, Siva, PUMA, and Noxa under 
stress situations (100). Recently, Dong’s group using two Bax-deficient mouse models, 
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found that only conditional Bax deletion specifically from proximal tubules could 
ameliorate IRI. Systemic deletion of Bax enhanced neutrophil infiltration without 
significant effect on kidney injury (169). Our data in chapter 1 indicate that expression of 
Bax, Bid and Siva are induced in ischemic kidneys but attenuated in p53 KO mice.  The 
significance of Bid and Siva expression in IRI was previously reported. In a previous 
report, Dong’s group demonstrated that Bid deficiency attenuated tubular disruption, 
tubular cell apoptosis, and caspase-3 activation during 48 h of reperfusion (172). 
Previous studies from our lab reported that the expression of the pro-apoptotic p53 
target Siva, and its cognate receptor CD27, is highly upregulated and co-expressed in 
the ischemic rat and mouse renal tissues (146), indicating that Siva plays a critical role in 
apoptosis following IRI. It is likely that synergic functions of these pro-apoptotic 
molecules may lead to the execution of apoptosis after IRI (183). 
The mechanisms of p53-mediated necrosis 
p53, MPTP and mitochondrial dynamics  
The MPTP-dependent necrosis is a common type of cell death in ischemia-
reperfusion injury because of the associated mitochondrial Ca2+ overload and ROS 
production (58). ROS and Ca2+ are two of the major inducers of MPTP-mediated 
necrosis via activation of CypD.  Accordingly, genetic deletion of CypD in mice led to 
significant protection against renal IRI as demonstrated by increased renal function and 
morphological protection (34). CypD deficient mice have less tubular necrosis as 
compared with wild type mice after the IRI (34) and these data have been subsequently 
bolstered by others (133).  
It was shown that in mitochondria isolated from Bax/Bak double knockout mice, 
oxidative stress triggers the p53 translocation to the mitochondria and induces the 
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formation of a CypD-p53 complex that promotes MPTP opening and necrosis (160).  
Recently, Vaseva et al. (160) showed that p53 may also be implicated in necrotic cell 
death through its interaction with CypD in the inner membrane of mitochondria, and 
subsequent opening of MPTP. These results were supported by independent studies 
demonstrating p53-CypD interaction in MPTP-dependent necrosis in different cell 
models, including neuronal (190), pancreatic (23), and osteoblast cells (191). The 
translocation of p53 to the mitochondria is shown to be dependent on dynamin-related 
protein 1 (Drp1), a mitochondrial fission protein.  Drp1 mediates the mono-ubiquitination 
of p53 by MDM2 to facilitate its translocation to induce necrosis in the setting of oxidative 
stress (60).  Inhibition of Drp1 by the Drp1 peptide inhibitor P110 prevented p53 
association with the mitochondria and reduced brain infarction in rats subjected to brain 
ischemia/reperfusion injury (60).  
Indeed, our data showed significantly reduced tubular cell necrosis in the outer 
medulla of p53 KO mice kidneys compared to WT after IRI (chapter 1, Fig. 5). The role 
of CypD in necrotic cell death after IRI is established previously by our lab and other 
groups (34, 113).  Two key factors involved in CypD activation are redox stress and 
calcium mishandling. Our data indicate that p53 deletion can decrease oxidative stress, 
which could be a potential mechanism by which p53 inhibits necrosis in renal PT cells. 
Can p53 translocate to mitochondrial matrix and interact with CypD to open the MPTP 
after IRI?  Our attempts to locate p53 to the mitochondria in various in vitro and in vivo 
models failed, suggesting that this may not be a prominent mechanism by which p53 
induces necrosis in renal PTC (see chapter 2, figure 22).  In our in vitro model, we tried 
to overexpress GFP-p53 in the cell and localize it after injury. To our surprise, GFP-p53 
was mainly located in the nucleus rather than the cytoplasm of mitochondria. These data 
suggest that the mitochondrial translocation of p53 after ROS injury is not the main 
mechanism of p53-induced necrosis. Although the p53 mitochondrial translocation 
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provides a novel mechanism by which CypD is activated by p53 to trigger MPTP, a few 
questions regarding the universal nature of this interaction in MPTP remain to be 
answered. For example, the formation of MPTP in mitochondria lacking p53 and the 
absence of p53 involvement in calcium-induced MPTP opening are intriguing (86).  Our 
data cannot exclude the possibility that GFP-p53 has changed the molecular behavior of 
its original form, although the localization signaling is not at the same end of p53 protein. 
Further studies using cell fractions that can better distinguish cellular organelles are 
needed to clarify those questions. It will be also important to know the effects of double 
knockout of p53 and CypD on the kidney after IRI. 
The interaction of a multichaperone complex comprising heat shock protein 60 
(Hsp60), Hsp90, and TNFR-associated protein-1, to CypD (82) to regulate MPTP has 
been previously establishedin tumor cells (54). A recent report by Lam et. al. 
demonstrates that a newly identified partner of Hsp90, the hematopoietic-substrate-1 
associated protein x-1 (HAX-1) is involved in the regulation of CypD in the heart.  HAX-1 
binds to CypD and interferes with its binding to Hsp-90, rendering CypD ubiquitination 
and degradation, resulting in protection against MPTP opening and cell death (105). The 
connection between CypD and the chaperone protein has never been investigated in IRI 
model. Our data did not show any changes in the expression level of CypD after IRI (see 
chapter 4). It suggests that the expression of CypD is not a major regulatory mechanism 
to modulate the function of CypD upon IRI. 
p53 and MOMP 
 The MOMP is required for the execution of necrotic cell death as it forms part of the 
MPTP. Although Bax and Bak were considered as proapoptotic molecules, emerging 
evidence clearly demonstrate that Bax and Bak are integral components of the MOMP of 
the MPTP.  p53 can control the MOMP by (1) regulating the expression and function of 
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Bax and Bid at the transcriptional level (99); (2) direct interaction with pro-apoptotic 
Bax/Bak  and anti-apoptotic Bcl2 to modulate the pore activity (28) and (3) suppressing 
Bcl2 expression via activation of microRNAs (21). However, the role of p53 in regulating 
Bcl2 family members to elicit necrosis remains undefined.    
Bax/Bak in their non-oligomerized form induced  a low level of permeability of the 
outer mitochondrial membrane, that is distinct from its mode of releasing cyt c in 
apoptosis, and permits necrosis through the MPTP (84). However, the role of p53 in 
regulating Bax/Bak is context-dependent. For example, muscle-specific deletion of Bax, 
but not p53, significantly reduced skeletal muscle necrosis and dystrophic pathology in a 
mouse model of muscular dystrophy (57). On the other hand, our data demonstrated 
significant decrease in necrosis in PTp53 KO ischemic kidneys possibly through 
diminished expression of PARP-1 and Bax (183).   
Our findings that expression of Bax are induced in ischemic kidneys but attenuated 
in PTp53 KO mice could suggest the involvement of p53 and Bax in both apoptosis and 
necrosis, since the mitochondrial swelling and rupture are reduced in the absence of 
Bax/Bak. Although we did not directly test this hypothesis, recent studies from another 
group reported that double knockout of Bax/Bak gene reduced a non-apoptotic cell 
death in the kidney after IRI (169). This suggests that the p53-Bax/Bak pathway might 
be indeed involved in necrotic cell death after IRI.  
p53 and ferroptosis 
As discussed earlier, ferroptosis is a type of iron-dependent cell death characterized 
by accumulation of lipid peroxides (108).  Ferroptosis is characterized by the presence of 
small mitochondria with condensed membrane densities. Usual morphological features 
of necrosis such as chromatin condensation, plasma membrane rupture, swelling of 
cytoplasmic organelles, or the formation of cytoplasmic vesicles/vacuoles, were not 
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observed in ferroptosis (37). Lipid peroxidation and ferroptosis are inhibited 
physiologically by antioxidant mechanisms including Gpx4, an enzyme, whose function 
depends on the glu/cys antiporter in the plasma membrane known as system Xc-.  
SLC7A11, together with SLC3A2, mediates cystine-glutamate exchange (47, 79, 176).  
Decreased cystine transport results in reduced intracellular glutathione (reduced form) 
levels and increased production of ROS (37).  A recent report shows that p53 activation 
suppresses transcription of SLC7A11, leading to reduced cystine uptake, intracellular 
GSH and consequent increased ROS levels. Thus, the sensitivity to ROS-induced 
ferroptosis is increased in cells with activated p53.  The effect of p53 on ferroptosis was 
independent of the ability of p53 to induce cell cycle arrest or apoptosis as a p53 mutant 
(p53 KR) lacking these functions retained the capacity to induce ferroptosis (79).  Further, 
erastin-induced ferroptosis was not prevented by inhibitors of autophagy, apoptosis or 
necroptosis suggesting that regulation of cystine uptake by p53 to promote ferroptosis is 
a distinct mechanism (79). However, it should be noted that this study did not exclude 
the possibility that CypD could be a downstream responder after p53 activation, even 
though MPTP driven necrosis and ferroptosis are reported to be distinct mechanisms (37, 
118). 
Our data suggest that by decreasing the expression of SLC7A11, activated p53 
plays a role in mediating ferroptosis. Indeed, when ferroptosis inhibitor ferrostatin-1 was 
administered into PARP-1 single knockout mice, we observed a better kidney function in 
those mice. It suggests the ferroptosis after IRI is conducted through a p53-mediated 
mechanism. Interestingly, PARP-1/PTp53 double knockout mice have the highest level 
of SLC7A11 expression than the respective single knockout mice, suggesting that the 
involvement of PARP-1 in controlling SLC7A11 expression, which has not been reported 
in any previous studies. The effect of both PARP-1 and p53 on the ferroptosis pathway 
can partially explain why double knockout mice have better kidney function and less 
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necrosis-like cell death. Future in vivo and in vitro studies using PARP-1/PTp53 DKO or 
PTp53 single knockout mice and cells with ferrostatin-1 inhibitor might clarify the exact 
role of PARP-1 and p53 in ferroptosis.  
p53 and inflammation in IRI 
Inflammatory cells such as neutrophils, monocytes/macrophages, and T cells are 
major players in the pathophysiology of renal IRI in animal models and in human AKI (6, 
7, 89, 148), Blocking the inflammatory reaction in the kidney is shown to prevent renal 
function deterioration and histological damage.  A recent study from Sutton et al. (152) 
utilized bone marrow transplantation to produce chimeric mice lacking p53 in leukocytes 
and demonstrated that p53 deletion prevents leukocyte apoptosis and increases their 
potential for cytokine secretion and thus worsens the pathophysiology of IRI. This study 
also demonstrated that systemic deletion of p53 can worsen the injury.  Our studies 
using mice lacking p53 in PT showed that it can profoundly decrease the infiltration of 
leukocytes and thus protect the kidneys from IRI, while p53 global knockout rats had 
significant increased inflammatory reaction similar to wild type rats. The apparent 
paradox in these data from the two studies could be due to the variations in the 
experimental protocol, the differences between the animal models, and the differing 
effects of inhibition of p53 in specific cell types within the kidney (183). 
p53 and fibrosis after IRI 
p53 is well known for its role in cell cycle regulation. The role of cell-cycle arrest and 
tubular apoptosis on the fibrogenic response of kidney tissue has recently been 
established in different injury models of CKD (180). The cell cycle arrest at G1/G0 or 
G2/M phase after injury switches tubular cells into a profibrotic phenotype with an 
increased expression and release of TGF-β, thereby promoting fibrosis (180). The effect 
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of pharmacological inhibition of p53 using pifithrin-α in fibrosis development after IRI was 
previously examined by two groups (32, 180), but with opposing results as detailed 
above.  Although the exact cause of these differing results is not clear, the different 
species and the timing of p53 inhibition in the two experiments may have contributed. 
Our data indicate that G2/M cell-cycle arrest occurs after IRI in WT mice but not in 
PTp53 KO mice, as demonstrated by reduced phospho-histone-3 staining, and may 
contribute to the attenuation of fibrosis. PT-specific deletion of p53 downregulated p21 
expression suggesting that it may titrate the level of p21 which allows the cells to 
progress through G2 and into M phase. On the other hand, our data demonstrate that 
PTp53 deletion can prevent inflammation and both necrotic and apoptotic cell death.  
Although it is unclear if the severity of the injury after an ischemic episode directly affects 
the progression of chronic kidney disease, it is likely that the attenuated inflammation 
and injury in the PTp53 KO mice may contribute to the decreased fibrosis. Further 
studies are needed to answer this question (183). 
PARP-1-mediated necrosis in AKI 
Our lab previously reported that pharmacological inhibition or gene ablation of 
PARP-1 protects rats and mice kidneys from ischemic injury (124, 192). These data 
have shown that in ischemic kidneys, PARP-1 expression and activity significantly 
increased specifically in the S3 segments of the proximal tubule. PARP-1 inhibition 
protects from IRI by improving renal function and tissue morphology, attenuated ATP 
depletion, leukocyte infiltration and activation of inflammatory molecules. An interesting 
observation from these studies is that PARP-1 inhibition blocked necrosis but had no 
effect on apoptosis.  These results suggest that necrosis and inflammation are primary 
mediators of ischemic renal injury (124, 192).  Similarly, data from our lab showed that 
PARP-1 deficiency reduced cisplatin-induced kidney dysfunction, oxidative stress, and 
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tubular necrosis, but not apoptosis (91). Moreover, neutrophil infiltration, activation of 
nuclear factor-κB, c-Jun N-terminal kinases, p38 mitogen-activated protein kinase, and 
upregulation of pro-inflammatory genes were all abrogated by PARP-1 deficiency. It 
demonstrated evidence for a PARP-1/TLR 4/p38/TNF-α axis following cisplatin injury, 
suggesting that PARP-1 activation is a primary signal and its inhibition/loss protects 
against cisplatin-induced nephrotoxicity (91). Collectively, these data suggest that 
targeting PARP-1 may offer a potential therapeutic strategy for both cisplatin and IRI-
mediated AKI by preventing necrosis and inflammation.  
Although the energy catastrophe theory and parthanatos have been suggested to 
explain the mechanism of PARP-1-induced cell death, previous studies demonstrated 
that PARP-1 plays a critical role in energy depletion after AKI.  In the ischemic kidneys, 
lack of oxygen leaves the glycolytic metabolism as the main pathway for ATP production 
in proximal straight tubules, thick ascending limbs and collecting ducts located in the 
severely hypoxic outer medullary region. However, glycolytic capacity in PST is 
selectively inhibited under ischemic conditions accounting for the incurred selective 
damage (17, 125, 130, 178).  It was suggested that the differences in glucose utilization 
are not due to a difference in the distribution of glycolytic enzyme activities but due to a 
differential regulation of hemodynamic factors (138, 139). Studies from our lab, however, 
indicate that PARP-1 inhibits glycolysis specifically in the proximal tubule S3 segments 
by poly(ADP-ribosyl)ation of GAPDH. Decreased activity of GAPDH makes proximal 
tubular cells vulnerable to necrotic cell death when subjected to ischemic injury.  These 
data indicate that poly(ADP-ribosyl)ation of GAPDH and the subsequent inhibition of 
anaerobic respiration exacerbate ATP depletion and induce necrosis selectively in the 
proximal tubule cells after IRI. 
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Cross talk between defined necrotic pathways 
The distinctive and overlapping roles of PARP-1 and p53 in IRI 
Cellular stress such as DNA damage, oncogene activation or hypoxia can activate 
and stabilize p53 (99, 166). The direct consequences of p53 activation depend largely 
on the initial stress, the level of p53 expression and activation and the cellular milieu, in 
which different factors that modulate various signaling pathways, to elicit apoptosis, 
autophagy, cell cycle arrest or necrosis (165, 167). PARP-1 is also activated by various 
agents capable of inducing DNA breaks, including reactive oxygen and nitrogen species, 
ionizing radiation and alkylating agents (68).  As discussed earlier, PARP-1 activation 
could lead to necrotic cell death by different mechanisms, although the initial response to 
DNA damage by both p53 and PARP-1 is to repair the damaged DNA and thus maintain 
genomic integrity (73, 80).   
The interaction between p53 and PARP-1 was reported previously in several studies.  
In aging cells undergoing telomere shortening, PARP-1 binding was shown to be critical 
for p53 activation and function (161). A reciprocal regulation of PARP-1 by p53 was 
described by Montero et al. (127) in ROS-induced cell death.  Genetic deletion of p53 
conferred increased resistance to ROS and PARP-mediated necrotic cell death in 
various cell types (127). PARP activity at baseline and after ROS stimulation was 
reduced in the absence of p53. The mechanism by which p53 regulates PARP-1 
activation and necrosis, in the setting of ROS-induced DNA damage, remains to be 
defined. Interestingly, inhibition of PARP-1-mediated necrosis led to p53-mediated 
caspase activation and apoptosis. p53 can also induce necrotic cell death in response to 
ROS-induced DNA damage, through the activation of the lysosomal cysteine protease 
cathepsin Q (156). Our data in chapter 1 and 2 also established a regulatory effect of 
p53 on the expression of PARP-1.  
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In chapter 1, we showed that PTp53-KO mice had significantly reduced levels of 
plasma creatinine and BUN after IRI, and improved renal morphology compared to WT 
mice (183). Quantitative studies indicated that necrosis is significantly reduced in the 
PTs after IRI.  Although the mechanism by which p53 deletion results in decreased 
necrosis is not defined, our results demonstrated that the expression level of PARP is 
attenuated in PTp53 KO compared to wild type mice ischemic kidneys. In chapter 2, we 
went further to look at the regulatory effect of p53 on the expression of PARP-1 in vitro. 
Indeed, in our injury model, hypoxia-reoxygenation increased PARP-1 expression in WT 
primary cell culture, but it was attenuated in p53 KO cells. When we overexpressed 
GFP-p53 in LLC-PK cells, it increased PARP-1 expression. These data suggest that 
PARP-1 expression is regulated by p53 in ischemic kidneys and tubular cells.  
Our novel finding that p53 inhibition can downregulate PARP-1 expression in kidney 
suggests that this could be an alternate mechanism by which p53 regulates necrosis 
after IRI.  Activation of PARP-1 is required for DNA repair, but excessive activation leads 
to necrotic cell death by depletion of intracellular ATP (61, 62).  Data from our lab 
previously reported that pharmacological and genetic inhibition of PARP-1 can 
prevent kidney dysfunction, oxidative stress, inflammation and tubular necrosis, but not 
apoptosis after ischemia/reperfusion (35, 124), and cisplatin nephrotoxicity (91).   
Although the activation of p53 up-regulates PARP-1 expression after IRI, both 
molecules have their own unique roles in the pathogenesis of IRI. In chapter 3, we 
explored the response of double knockout of PARP-1 and PTp53 in the kidney to IRI. 
PTp53 knockout kidney had less neutrophils infiltration and reduced TUNEL positive 
cells compared with PARP-1 single knockout mice, indicating a unique role of p53 in 
apoptosis and inflammation. PTp53 knockout mice also had better kidney function 
performance and histological score. On the other hand, PARP-1/PTp53 DKO mice 
showed even better kidney function and histological score, suggesting deletion of PARP-
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1 in the kidney added more protective effect than knockout of PTp53 alone. These 
unique and overlapping roles of PARP-1 and p53 can explain why PARP-1/PTp53 DKO 
mice have the best renal protective effects. Targeting those molecules might achieve 
better effects when considering blocking necrotic pathways.   
Is MPTP required for PARP-1-induced necrosis? 
 It was not clear if PARP-1 medicated necrosis and CypD-mediated MPTP are two 
independent pathways. Xu et al. (177) proposed that PARP-1 activation is mediated 
through the pro-necrotic kinase RIP1-JNK1 axis, which induced necrosis through MPTP.  
Data from Alano et al. also suggested that PARP-1-mediated NAD+ depletion could lead 
to MPTP opening and necrosis.  However, Dodoni et al. demonstrated that the alkylating 
agent could directly induce MPTP independent of PARP-1 suggesting that the MPTP 
pore may in fact be upstream of PARP-1 activation and NAD+ depletion (38). Further, 
inhibition of PARP-1 failed to block TNFα-induced necrosis and inhibition of RIP1 or 
RIP3 could not prevent PARP-1-induced necrosis (149). In addition, the protective 
effects of RIP1 and PARP-1 are additive in oxidative-stress induced necrosis suggesting 
that they represent separate necrotic pathways (149). It is also noteworthy that although 
a role for MPTP in PARP-1-induced AIF translocation is suggested by two reports (2, 29), 
a recent study suggest that PARP-1 and MPTP can induce necrosis independent of 
each other (40).   
In chapter 4, we showed that double knockout of PARP-1 and CypD in the kidney 
significantly attenuated the declination of kidney function after IRI compared with wild 
type mice. Although PARP-1 and CypD single knockout mice had reduced necrotic 
tubules in the outer medulla, their kidney function was not well preserved as double 
knockout mice. This suggests that PARP-1- or CypD-induced necrosis is also involved in 
the pathogenesis of IRI and they are likely independent pathways. Interestingly, animals 
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with both genes deleted had less apoptotic cell death and even lower inflammatory 
infiltration in the kidney, which supports the notion that double knockout of PARP-1 and 
CypD additively protects kidney from IRI. Collectively, these data suggest that PARP-1 
and CypD-mediated necrotic pathways may be independent of each other. Since we 
cannot totally exclude other possible mechanisms that make double mice more resistant 
to IRI, future studies using PARP-1/CypD PT-specific knockout mice may be useful to 
exclude other factors from the system. 
To our knowledge, this is the first study that looked at the renal protective effects of 
PARP-1/PTp53 and PARP-1/CypD double knockout mice in IRI. Previous studies using 
single gene ablation of these genes achieved moderate renal protective effects. In this 
study, however, we showed that double knockout of PARP-1/PTp53 or PARP-1/CypD 
has significantly better protective effects than their individual single knockout mice. It 
suggests that the pathogenesis of AKI is a far more complicated process with the 
participation of multiple cell death pathways. Since double knockout mice still have 
kidney injury after IRI, it raises an interesting question: Will blocking more necrotic cell 
death pathways will further protect the kidney from IRI? Future studies using triple 
knockout mice might be able to answer this question. In addition, tubular specific 
knockout mice might provide more information about the specific role of PARP-1 and 
CypD in the proximal tubular cells, and delineate the downstream mechanisms of 
necrosis after IRI.  
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Conclusion 
Acute kidney injury is a common clinical syndrome with no effective treatment, 
indicating an incompletely understood pathophysiology. Our data established the 
importance of p53-induced necrotic cell death in this syndrome. Other molecules 
including PARP-1, Bax/Bid, and CypD participate in necrotic cell death insinuate that 
integration of their signaling pathways may be required to elicit necrotic cell death in IRI. 
Although the hierarchy of their activation, physical interactions and crosstalk between 
these molecules and how these molecules interact and integrate their functions to elicit 
necrosis in distinct AKI settings remain largely undefined, our data from double knockout 
mice suggest that PARP-1- and CypD-induced necrosis are likely independent pathways 
while p53- and PARP-1- induced necrosis might overlap to some extent. Targeting 
necrotic cell inducers such as p53, PARP-1, and CypD might be useful therapeutic 
methods in treating this disorder. In particular, our data demonstrate that p53 has 
profound effects on tubular cell necrosis, ferroptosis, and apoptosis after IRI. Although 
targeting proximal tubular cell death by modulating p53 or its downstream signaling 
pathways may provide an efficient therapeutic strategy for IRI, combination therapies 
that target multiple modalities of cell death may be required to completely prevent 
necrosis and maintain renal function (see figure 37). 
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Figure 37: Molecular mechanism of necrotic cell death in ischemic renal injury.  
In the ischemic renal injury model, necrosis in proximal tubular cells is a common type of 
cell death. Initial injury results in DNA damage and rapid activation of p53 and PARP-1. 
p53 induces the expression of Bax, which will facilitate the MOMP for necrosis. Activated 
PARP-1 will rapidly deplete intracellular NAD+ and ATP, and simultaneously inhibit 
GAPDH, which reduces glycolytic capacity in proximal tubules. p53 induced TIGAR 
expression inhibits the rate limiting PFK and the glycolytic pathway. The severe ATP 
depletion from glycolytic inhibition and PARP-1 activation shuts down ion homeostasis 
resulting in Ca2+ influx and uptake into mitochondria. PARP-1 as a transcriptional 
cofactor induces several cytokines and promotes infiltration of inflammatory cells to the 
injured renal parenchyma, all leading to increased ROS production. ROS and Ca2+, the 
most prominent mediators of permeability transition, increase the probability of MPTP 
opening via activation of CypD and the ATP synthasome complex. Osmotic influx of 
water and solutes into the mitochondrial matrix leads to mitochondrial swelling and 
rupture of outermembrane, to elicit mitochondrial dysfunction and necrosis.  Although 
recent evidence suggests that p53 can mediate ferroptosis by regulating the expression 
of SLC7A11, this pathway has not been tested in ischemic renal injury model. The 
contribution of necroptosis in proximal tubule cell death has recently been challenged 
and the mechanism by which RIP1K blockade prevents renal injury remains to be 
elucidated.  Although, recent evidences suggest p53 translocation to mitochondrial 
matrix and activation of CypD, such a role for p53 is not established in kidney injury 
(184).   
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